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 Alzheimer’s disease (AD) is the most common form of dementia caused, arguably, by 
the accumulation in the brain of ‘sticky’ protein fragments called amyloid beta (A)-peptides. 
These fragments are formed through the proteolytic cleavage of the amyloid precursor 
protein (APP) by β- and γ-secretases. However, in an alternate non-amyloidogenic pathway, 
α-secretase (ADAM10) cleaves APP within the A-domain thereby precluding the formation 
of intact toxic peptides.  
 We have recently shown that orphan drug dichloroacetate (DCA) can inhibit the 
detrimental amyloidogenic APP processing pathway whilst boosting the beneficial non-
amyloidogenic processing pathway. However, the mechanism(s) by which DCA exerts these 
effects are, as yet, unknown and, therefore, the current study aims to elucidate these 
mechanisms. Hence, through manipulating pH, p53 levels, lactate dehydrogenase (LDH) 
activity, pyruvate and lactate levels, mitochondrial autophagy and oxidative stress, we aimed 
to investigate each potential mechanism by characterising the resultant effects on APP 
expression and proteolysis. Furthermore, we also investigated the potential effects of DCA on 
the subcellular localisation of APP and the activity of BACE1. However, none of these potential 
mechanisms proved to be involved in the DCA mechanism of action. Therefore, in conclusion, 
the mechanism(s) behind DCA-mediated changes in APP proteolysis/expression have not yet 
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1.  Literature Review. 
1.1.  Alzheimer’s Disease. 
 The ageing global population has driven a dramatic increase in neurodegenerative 
disease within the last 20 years, reaching an estimated 50 million dementia patients in 2018 
(World Health Organisation, 2018). This figure is expected to triple over the next 30 years, 
reaching approximately 150 million patients by 2050 (Dementia Statistics Hub, 2018), 
highlighting the importance of research in this field. 
 Alzheimer’s disease (AD), which accounts for 60–70 % of dementia cases, was initially 
described by Alois Alzheimer in 1907 (Sanabria-Castro et al., 2017). Through studying his 
patient, Auguste Deter, Alzheimer defined AD as an “unusual disease of the cerebral cortex”, 
resulting in hallucinations, memory loss and death. It has since been determined that the 
brains of AD patients are characterised by the degradation of neurons and synapses (Robinson 
et al., 2018), resulting in several clinical features. These clinical features develop slowly and 
progressively, initially affecting short-term memory, advancing to aphasia, apraxia and 
agnosia, and eventually resulting in premature death (Macdonald et al., 2018). 
 The pathological hallmarks of AD include deposition of amyloid-β (Aβ) plaques and 
neurofibrillary tangles within the brain (Sanabria-Castro et al., 2017) (Fig. 1.1.). The Aβ 
plaques are composed of thick fibrils consisting of 40–43 amino acid Aβ-peptides, whereas 
neurofibrillary tangles consist of paired helical filaments made up of hyperphosphorylated 
tau protein (Kamat et al., 2014).  
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 One of the leading theories as to the causation of AD, called the “Amyloid Hypothesis”, 
suggests that the widespread degradation of neuronal matter observed in AD is a result of Aβ 
plaque formation (Hardy and Selkoe, 2002; Sanabria-Castro et al., 2017). It suggests that the 
other hallmarks associated with AD arise due to the disproportional rates of Aβ formation and 
degradation, following changes in the proteolytic processing of the amyloid precursor protein 
(APP) (Hardy and Allsop, 1991).  
 
1.2.  Amyloid precursor protein proteolysis. 
APP is a type-1 membrane protein containing a large extracellular amino-terminal 
region and a small cytosolic carboxyl-terminal region (Coronel et al., 2018). Composed of 170 
kb and 19 exons, the APP gene is alternatively spliced to generate 8 isoforms ranging in length 
from 365 to 770 amino acids (Holsinger et al., 2013). The predominant transcript within the 
Figure 1.1. Pathology of an AD brain. Hallmark amyloid plaques and tau tangles visualised within an AD 
brain. (Image adapted from Blennow et al., 2006). 
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central nervous system is the 695 amino acid isoform, whereas the predominant forms within 
other cell types are the 751 and the 770 amino acid isoforms (Coronel et al., 2018). 
APP contains several different domains (Pandey et al., 2016). The large extracellular 
region consists of two domains, called E1 and E2 (Fig. 1.2.), connected by the acidic domain 
(AcD). The E1 domain is further divided into the growth-factor-like domain (GFLD) and the 
copper-binding domain (CuBD), whereas the E2 domain consists of the central APP domain 
(CAPPD). E2 is attached to the juxtamembrane region (JMR), which is adjoined to the APP 
intracellular domain (AICD) via a single transmembrane helix. The longer 751 and 770 amino 
acid APP isoforms also contain an additional Kunitz-type protease inhibitor domain (KPI) and 
the latter further possesses an OX-2 sequence (Coburger et al., 2013). 
 
Figure 1.2. The domain composition of the amyloid precursor protein. The extracellular domain is composed 
of the E1 and E2 domains which are linked by an acidic domain (AcD). E1 is composed of a growth-factor-like-
domain (GFLD) and a copper-binding-domain (CuBD). E2 is composed of a central APP domain (CAPPD). 
Additionally, a juxtamembrane domain (JMR) is bound to a single transmembrane helix which is bound to the 
APP intracellular domain (AICD). The longer 751 and 770 amino acid APP isoforms also contain an additional 
Kunitz-type protease inhibitor domain (KPI) and the latter further possesses an OX-2 sequence. (Image adapted 
from Coburger et al., 2013). 
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After it is synthesised within membrane-bound polysomes, APP undergoes  
post-translational alterations (such as glycosylation, phosphorylation and sulphonation) and 
is transported to the surface membrane, or remains within the trans-Golgi network (TGN) 
(Plácido et al., 2014). 
APP is then cleaved via several proteolytic pathways including the ‘amyloidogenic’ and 
‘non-amyloidogenic’ pathways (Fig. 1.3.). The former of these two pathways occurs primarily 
in the late endosomes and leads to the production of the neurotoxic Aβ-peptides found in 
plaques (Coronel et al., 2018). Here, β-secretase cleaves APP to produce sAPPβ and a  
carboxy-terminal fragment (β-CTF or C99). This β-CTF is then cleaved by γ-secretase to 
produce Aβ (4 kDa) and soluble AICD, which is involved in nuclear signalling (Eggert et al., 
2018). Conversely, in the non-amyloidogenic pathway (Fig. 1.3.), α-secretase cleaves APP to 
produce sAPPα and a truncated CTF (α-CTF or C83). This α-CTF lacks the N-terminal region of 
the Aβ domain, and so γ-secretase cleavage leads to the production of a truncated Aβ protein 
called p3 (3 kDa), along with soluble AICD. The sAPPα produced during the non-amyloidogenic 
pathway has neuroprotective qualities, boosting memory and preventing Aβ-related 
degeneration (Mattson et al., 1993; Coronel et al., 2018). 
The amyloidogenic and non-amyloidogenic pathways are thought to be reciprocal in 
nature, with α-secretase enhancement inducing reductions in Aβ production (Nitsch et al., 
1992; Postina et al., 2004). Therefore, it has been suggested that inhibiting the activity of β- 
or γ-secretase, or enhancing the activity of α-secretases, could be possible therapeutic targets 
for AD (Wang et al., 2016; Gu et al., 2017; Bhatt et al., 2018). 
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1.2.1.  α-secretases. 
 In most cells, >90 % of APP is processed via the non-amyloidogenic pathway, in which 
APP is cleaved between Lys16 and Leu17 of the Aβ sequence by an α-secretase activity (Yuan 
et al., 2017; Eggert et al., 2018). This enzymatic activity can be described as having both 
basal/constitutive and regulated forms; the latter being stimulated by phorbol ester 
activators of protein kinase C (PKC) (Wang et al., 2016).  
 Several different enzymes have been implicated in α-secretase activity, primarily 
members of the a disintegrin and metalloprotease (ADAM) family (Wang et al., 2016). For 
example, Lammich et al. (1999) observed an increase in both basal and PKC-stimulated sAPPα 
production in ADAM10-overexpressing HEK293 cells. The authors also demonstrated that 
endogenous α-secretase activity was inhibited by transfecting HEK293 cells with a dominant 
 
Figure 1.3. The non-amyloidogenic and amyloidogenic APP processing pathways. (A) The non-amyloidogenic 
pathway generates sAPPα, p3 and AICD through APP cleavage by the α- and γ-secretases. (B) The amyloidogenic 
pathway generates sAPPβ, Aβ and AICD through APP cleavage by the β- and γ-secretases. (Image from Haass 
et al., 2012). 
A.   Non-amyloidogenic processing           B.   Amyloidogenic processing 
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negative form of ADAM10, containing a point mutation in the zinc binding site. Postina et al. 
(2004) also demonstrated the role of ADAM10 as an α-secretase, using transgenic mice 
overexpressing ADAM10 to show that the enzyme reduced brain plaque load and improved 
spatial learning relative to control animals, whereas overexpression of a dominant negative 
form of the enzyme led to an enhanced plaque load. Furthermore, Jorissen et al. (2010) 
generated conditional ADAM10 knockout mice by crossing Nestin-Cre transgenic mice with 
LoxP flanked ADAM10 mice. Global ADAM10 knockout mice usually die at embryonic day 9.5, 
but this system ablated ADAM10 expression specifically within neuronal cells, significantly 
enhancing the survival of the embryos. Although the mice died perinatally, they survived long 
enough for the identification of dramatically lower α-secretase activity in the embryonic 
brain, confirming the identity of ADAM10 as an α-secretase and suggesting it was responsible 
for a large proportion of basal α-secretase processing. 
  ADAM9 was also put forward as a potential α-secretase by Koike et al. (1999), who 
demonstrated that APP was cleaved specifically at the α-secretase site when co-expressed 
with ADAM9 in COS cells.  The authors also found that inhibiting ADAM9 with the 
hydroxamate-based metalloprotease inhibitor, SI-27, enhanced β-secretase processing of 
APP, suggesting a reciprocal relationship between the non-amyloidogenic and amyloidogenic 
pathways. Additional studies have demonstrated that ADAM9 does not function as a 
secretase directly, but instead mediates the cleavage of APP through ADAM10 (Parkin and 
Harris, 2009; Tousseyn et al., 2009). Parkin and Harris (2009) showed that ADAM10 itself 
could be shed by ADAM9 from the surface of HEK293 cells and that the shed form of the 
former enzyme was unable to cleave APP. Additional work by Tousseyn et al. (2009) found 
that ADAM10 shedding was decreased in ADAM9-deficient mouse embryonic fibroblast (MEF) 
cultures, and almost completely ablated in cells lacking both ADAMs 9 and 15, suggesting that 
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these two latter enzymes are both involved in ADAM10 shedding. As such, it would appear 
that ADAMs 9 and 15 are not true α-secretases but somehow work through ADAM10 to 
enhance the production of sAPPα. 
 Buxbaum et al. (1998) showed that primary embryonic fibroblasts from ADAM17 
knockout mice had much lower regulated α-secretase function. Additionally, Slack et al. 
(2001) found that, when ADAM17 expression was enhanced in HEK293 cells, so too was sAPPα 
production. Caccamo et al. (2006) then suggested that ADAM17 acts as a regulated  
α-secretase, as M1 muscarinic acetylcholine receptor (M1AChR) activation in a mouse model 
resulted in downstream PKC activation and enhanced activity of an α-secretase, subsequently 
identified as ADAM17. 
It is now widely accepted that ADAM10 is the physiological constitutive α-secretase 
and ADAM17 probably a regulated secretase. However, it is worth noting that further studies 
have also implicated several other ADAM family members including ADAMs 8, 12 and 19 
(Wang et al., 2016). 
As previously mentioned, boosting α-secretase activity has been suggested as a 
possible treatment for AD (Kumar et al., 2018). For example, acitretin is a vitamin A analogue 
which has recently been investigated both in mouse models and clinical trials. In APP/PS1 
transgenic mice, this drug led to a significant reduction in Aβ and enhanced activity of 
ADAM10 (Tippmann et al., 2009). Phase II clinical trials, however, saw severe side effects such 
as cheilitis, peeling, alopecia and hepatotoxicity (Kumar et al., 2018). 
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1.2.2.  β-secretase.  
 The enzyme responsible for APP β-secretase cleavage is a 55.8 kDa transmembrane 
aspartyl protease called β-site APP cleaving enzyme-1 (BACE1) (Vassar et al., 1999; Yan et al. 
1999). Cai et al. (2001) demonstrated that this enzyme is the sole β-secretase in mice by 
showing that neurons from BACE1 knockout animals exhibited complete ablation of β-CTF 
and Aβ-peptide production.  
 BACE1 is initially synthesised within the ER and contains a short prodomain. This 
prodomain is then removed by post-translational modification within the Golgi and the 
protein is subject to several other modifications (such as glycosylation, phosphorylation, 
palmitoylation, ubiquitination and acetylation), allowing correct folding of the protease 
domain and enhanced enzymatic function (Araki, 2016; Sun and Roy, 2018). The mature 
BACE1 enzyme is membrane-bound and ubiquitously expressed in all tissues, with the highest 
levels identified in the pancreas and the brain (Prox et al., 2012). The relevance of high levels 
in the pancreas is not yet fully understood, but the high levels in the brain help to explain why 
this organ is susceptible to AD. 
 BACE1 is localised in several subcellular sites including the endosomal compartments, 
TGN and endoplasmic reticulum (Sun and Roy, 2018). Whilst non-amyloidogenic processing 
primarily occurs at the surface membrane (Plácido et al., 2014), cleavage by BACE1 mainly 
occurs upon re-internalisation to the endosomes or the TGN (Vassar et al., 2004). 
 BACE1 inhibition has been suggested as a potential therapeutic target for AD, 
preventing the production of Aβ. However, this enzyme is thought to have other important 
physiological roles with several additional substrates, such as low-density lipoprotein 
receptor (LDLR) -related protein, identified in a study by von Arnim et al. (2005). Studies have 
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also shown that BACE1 has an important role in myelination and that inhibition can lead to 
hypomyelination (Willem et al., 2006; Sankaranarayanan et al., 2008). Although this may not 
be a problem in humans as neurons are fully myelinated by adulthood when AD develops, 
studies have identified other toxic effects of BACE1 inhibition, such as vascular dysregulation 
and retinal pathology (Cai et al., 2001). 
More recently, BACE1 inhibition has been tested in various clinical trials. However, 
none of these have shown any positive effect on slowing or restoring cognitive decline despite 
reducing Aβ and sAPPβ levels (Kumar et al., 2018). For example, Verubecestat was designed 
as a BACE1 inhibitor which selectively prevented the deposition of Aβ in various animal 
models (rats, mice and monkeys). However, a recent stage III clinical trial in mild-to-moderate 
AD patients by Merck was abandoned in February 2018 following findings that patients had 
no improvements in cognition despite a reduction in Aβ levels (Kumar et al., 2018). 
Furthermore, these patients had increased falls, injuries, weight loss, and neuropsychiatric 
issues, including suicidal thoughts and sleep deprivation (Egan et al., 2018). 
 
1.2.3.  γ-secretase. 
 The final proteolytic step in both the amyloidogenic and non-amyloidogenic pathways 
is performed by a 230 kDa intra-membrane cleaving aspartyl proteinase complex called  
γ-secretase (Aguayo-Ortiz et al., 2018). This complex is composed of several distinct subunits: 
presenilins (PS) 1 or 2, nicastrin (NCT), anterior pharynx-defective 1 (APH-1) and presenilin 
enhancer 2 (PEN-2) (Zhang et al., 2014).  
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 The presenilins, which comprise the active component of the enzyme, were initially 
identified through genetic linkage analyses in familial AD families (Schellenberg et al., 1992; 
Levylahad et al., 1995). These studies identified two loci which were frequently mutated in 
AD patients on chromosomes 1 and 14, later identified through cloning and sequencing 
studies as PSEN1 which encodes PS1 (on chromosome 14) and PSEN2 which encodes PS2 (on 
chromosome 1) (Rogaev et al., 1995; Sherrington et al., 1995). The role of the presenilins in 
γ-secretase cleavage of APP was then directly demonstrated by De Strooper et al. (1998), who 
analysed γ-secretase function in PS1-deficient mouse embryos. They found that γ-secretase 
cleavage was almost completely ablated when PS1 was deleted, with no effect on α- and  
β-secretase function but a 5-fold reduction in Aβ production. Subsequently, studies have 
identified over 180 familial AD-linked mutations in the PS genes (Bursavich et al., 2016). 
Nicastrin was identified as a component of the γ-secretase complex through studies 
in C.elegans, in which the suppression of nicastrin expression resulted in the loss of  
γ-secretase function (Yu et al., 2000). This component functions as a co-factor, binding to 
substrates and functioning as a γ-secretase receptor (Zhang et al., 2014). Two additional  
co-factors, APH-1 and PEN-2, have also been identified through genetic screening in C.elegans 
(Francis et al., 2002). Although the presenilins are the active components of the γ-secretase 
complex, all four protein components are required for the γ-secretase to mature and function 
correctly (Fraering et al., 2004; Zoltowska and Berezovska, 2018). For example, one study 
identified that nicastrin is involved in the stability and trafficking of the mature complex 
(Zhang et al., 2005), whereas another showed that APH-1 maintains the physical interactions 
between the different components of the secretase complex (Lee et al., 2004). 
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  The γ-secretase complex has relaxed specificity and APP CTFs are cleaved at several 
sites (ε, ζ, and γ-sites) resulting in the production of final Aβ peptides containing between 37 
and 43 amino acids (Zoltowska and Berezovska, 2017). Approximately 90 % of Aβ produced is 
Aβ 1-40 and <10 % is Aβ1-42, the latter of which aggregates more readily to form the Aβ 
oligomers observed in AD (Duggan et al., 2016).  
 The exact process of APP CTF cleavage by γ-secretase is not fully understood. 
However, it has been suggested that the process occurs via a step-wise sequence of cleavages 
(Takami et al., 2009) starting with cleavage at one of two ε-sites, followed by cleavage at one 
of two ζ-sites and followed, finally, by cleavage at one of the γ-sites (Fig. 1.4.). The final 
cleavage at one of the possible γ-sites occurs most commonly at amino acid 42 or 40 (but may 
occur at amino acid 37, 38 or 39 instead), resulting in the generation of Aβ1-42 or 1-40 which is 
released into the extracellular space (Aguayo-Ortiz and Dominguez, 2017). 
 
Figure 1.4. Cleavage of APP by γ-secretase. APP is cleaved at three distinct but relaxed sites (ε-, ζ-, and γ-
sites) by γ-secretase, resulting in the production of Aβ, containing between 37- 43 amino acids. Initially, APP 
is cleaved at one of the possible ε-sites (green), either at amino acid 48 or 49. Next, the protein is cleaved 
at one of the possible ζ-sites (blue), either at amino acid 45 or 46. The final γ-site can occur at one of several 
sites (red), generating the final Aβ peptide of between 37 and 42 amino acids. (Image adapted from Haass 
et al., 2012).  
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 Several γ-secretase inhibitors have been investigated as possible AD treatments. For 
example, early clinical trials of Semagacestat saw significant dose-dependent decreases in Aβ 
plaque levels in the brains of AD patients (Henley et al., 2009). However, in a phase III clinical 
trial, several side effects were observed including skin cancers and reduced lymphocyte 
counts (Doody et al., 2013). These side effects are thought to be attributable to the role of γ-
secretase in the cleavage of Notch, which is processed in a similar manner to APP, producing 
transcriptionally active Notch intracellular domain (NICD) (Kumar et al., 2018). The trial was 
eventually abandoned because patients receiving Semagacestat also exhibited reductions in 
memory and cognitive function compared to placebo-treated patients, despite the reductions 
in Aβ generation. Another γ-secretase inhibitor, Avagacestat, has also been shown to result 
in a significant cognitive decline, brain atrophy and an increase in the incidence of skin cancers 
in AD patients treated with the drug relative to those receiving placebo (Coric et al., 2015). 
Largely in order to bypass the off-target effects, such as Notch signalling inhibition,  
γ-secretase modulators (GSMs) (as opposed to inhibitors) have recently been developed 
(Kumar et al., 2018). Rather than inhibiting the γ-secretase, these drugs interact allosterically 
either with the γ-secretase complex or the APP CTF substrates. Clinical trials of several of 
these modulators have resulted in decreased Aβ formation and enhanced non-amyloidogenic 
APP processing (Bursavich et al., 2016). These drugs commonly exhibit low efficacy and 
require very high doses (Kumar et al., 2018) but a newer generation of GSMs show promise 
as they have been developed to have improved bioavailability and stability, therefore 
requiring lower doses.  
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1.3. The amyloid cascade hypothesis. 
 Although currently the subject of great discussion due to the failure of multiple β- and 
γ-secretase inhibitors/modulators in clinical trials, the amyloid cascade hypothesis (Fig. 1.5.) 
suggests that AD is initially caused by an increase in Aβ generation from APP which exceeds 
the clearance of these peptides (Hardy and Allsop, 1991). This initial event then triggers a 
cascade resulting, ultimately, in neuronal dysfunction, the corresponding symptoms of AD 
and death. 
 The first clues in the identification of Aβ-peptides as the putative toxic entity in AD 
came in the form of similarities between dementia observed in Down syndrome and the 
former disease. Aβ was isolated and sequenced from the meningeal blood vessels of both AD 
and Down syndrome patients, suggesting a link between this peptide and the 
neurodegeneration observed in both conditions (Glenner and Wong, 1984). The following 
year, Aβ-peptides were also identified in senile plaques from AD brains (Masters et al., 1985). 
Sequencing studies then demonstrated that the APP gene was located on chromosome 21 
and that mutations in this gene could lead to AD (Goldgaber et al., 1987; Robakis et al., 1987; 
Hardy, 1992). These findings also agreed with previous observations in Down syndrome cases, 
as these patients have an additional copy of chromosome 21 and, therefore, have an 
additional APP gene (Querfurth et al., 2010). 




Figure 1.5. The Amyloid Cascade Hypothesis. When the production of Aβ42 exceeds its clearance, the peptides 
aggregate and form plaques. This event then triggers a cascade which eventually results in AD. (Image from 
Hardy and Selkoe, 2002).  
- 16 - 
 
1.4. Dichloroacetate. 
 Dichloroacetate (DCA) (Fig. 1.6.) is an orphan drug which was originally studied as a 
possible treatment for mitochondrial diseases, such as lactic acidosis (James and Stacpoole, 
2016), and has subsequently been investigated as a treatment for several other conditions 
including cancer, diabetes (Michelakis et al., 2008) and, more recently, AD (Parkin et al., 
unpublished data).  
 This small biomolecule (150 Da) can penetrate the blood-brain barrier with high 
bioavailability and is immediately absorbed when orally consumed (Stacpoole, 2017). The 
potential use of DCA in the treatment of lactic acidosis emanated from its identification as an 
indirect activator of the pyruvate dehydrogenase (PDH) (Kankotia and Stacpoole, 2014). Early 
studies in this field were promising and, in clinical trials, DCA reduced lactate levels and 
increased blood pH in lactic acidosis patients. However, these changes were later shown to 
have no significant effect on patient survival or disease-associated symptoms (Stacpoole et 
al., 1992) and further research revealed that many patients experienced long-term 
cumulative DCA toxicity (Stacpoole et al., 2012). Therefore, research into the use of DCA for 




Figure 1.6. Molecular structure of DCA. (Image adapted from Kato et al., 2007) 
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1.4.1.  Mode of DCA action. 
 The most important site of DCA action is at the PDH, an enzyme found within the 
mitochondria which catalyses the decarboxylation of pyruvate to acetyl-coenzyme A  
(acetyl-coA) (Fig. 1.7.).  
 The activity of the PDH is tightly regulated to ensure that the correct levels of aerobic 
and anaerobic oxidation are carried out in the cell. This regulation is largely through the action 
of two types of enzymes; pyruvate dehydrogenase phosphatases which dephosphorylate and 
activate the PDH, and pyruvate dehydrogenase kinase (PDK) which phosphorylates and 
deactivates the complex (Fig. 1.7.) (James and Stacpoole, 2016).  
 
Figure 1.7. The mechanism of dichloroacetate (DCA) action. DCA inhibits PDH kinase and, therefore, 
maintains PDH in its active, dephosphorylated form. As a result, there is an increased generation of acetyl-
coA from pyruvate catalysed by PDH. (Image from Mann et al., 2000). 
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 The primary mechanism through which DCA stimulates the PDH is through the 
inhibition of PDK, thereby ensuring that PDH is maintained in a dephosphorylated and active 
form (Neveu et al., 2016). The drug binds to the hydrophobic binding pocket in the N-terminal 
domain of PDK, preventing the kinase from binding to the lipoyl E2 domain of PDH and hence 
preventing phosphorylation (Mann et al., 2000; Stacpoole, 2017). Additionally, DCA can also 
cause a conformational change in the structure of PDK1, thereby blocking it from binding and 
phosphorylating the PDH (Kankotia and Stacpoole, 2014). Finally, DCA also inhibits the 
turnover of the PDH, preventing it from being broken down; however, the mechanism behind 
this latter process is currently unknown (Kankotia and Stacpoole, 2014). These mechanisms 
combine to result in an overall reduction in lactate levels, more acetyl-coA production and, 
therefore, more tricarboxylic acid cycle activity. 
 In recent years, DCA has been investigated as a possible treatment for cancer due to 
its ability to minimise the Warburg effect (Warburg et al., 1927), whereby cancerous cells 
switch energy generation away from oxidative phosphorylation in the mitochondria to 
glycolytic energy generation in the cytosol (Sun et al., 2018). DCA can reverse this process by 
minimising the availability of pyruvate, due to its enhanced utilisation by PDH (Stacpoole, 
2017). This leads to a greater production of acetyl-coA, more tumour dependency on oxygen 
and, therefore, more susceptibility to hypoxia-specific chemotherapy (Wang et al., 2017).  
DCA also enhances free radical generation and associated cellular oxidative stress 
through the increased aerobic respiration resulting from PDH activation (Hassoun and 
Cearfoss, 2011). The drug minimises the ability of the mitochondrial membranes to 
hyperpolarise and opens transition pores within them, driving an increase in ROS production 
(Dai et al., 2014). This enhanced ROS production and the associated increase in oxidative 
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stress have been proposed as another mechanism by which DCA promotes cancer cell death. 
It should, however, be noted that some studies have shown that specific tumour types have 
different responses to DCA and resistance to the drug can develop (Kankotia and Stacpoole, 
2014).  
 
1.5.  DCA as a regulator of APP expression and proteolysis. 
 Recent studies in our laboratory (Parkin et al., unpublished data) have demonstrated 
that DCA can enhance the non-amyloidogenic processing of APP in SH-SY5Y cells whilst 
impairing sAPPβ and Aβ generation via the amyloidogenic pathway. However, the molecular 
mechanisms regulating this phenomenon are not yet known and are, therefore, the subject 
of the current study. The theories/background underlying the specific mechanisms tested are 
discussed in the following sections.  
 
1.5.1.  Altered pH as a potential mechanism by which DCA regulates APP proteolysis. 
Sodium dichloroacetate is a sodium salt of dichloroacetic acid and, when in solution, 
acts as a base and raises the pH, making it more alkaline. DCA has also been shown to increase 
both extracellular and intracellular pH, most likely through decreased lactate levels as a 
consequence of drug treatment (Robey et al., 2011; Albatany et al., 2018).  
 Most studies suggest that, in Alzheimer’s disease, there is an increase in cerebral 
acidosis and lactate accumulation within the cerebral spinal fluid, overall leading to a large 
decrease in neural pH. Bowen and Davison (1986) and Yates et al. (1990) reported a decreased 
tissue pH in the AD-afflicted brain and the former study suggested that this was due to an 
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accumulation of lactate and an alteration of anion exchange protein expression. Decreased 
pH has also been directly implicated in Aβ-peptide generation and aggregation. Brewer (1997) 
showed that increased acidity led to enhanced Aβ levels in cultured rat hippocampal neurons, 
whilst acidification has also been shown to promote aggregation of these peptides in rodent 
models and immobilised Aβ fibrils (Atwood et al., 1998; Pirchl et al., 2006; Brannstrom et al., 
2014). 
The activity of APP cleaving secretases has been shown to be directly regulated by 
changes in pH (Brown et al., 1998). For example, BACE1 is known to function optimally at pH 
6 (Lin et al., 2000; Xiang et al., 2010). Furthermore, Hoefgen et al. (2015) showed that APP 
undergoes a conformational switch which is pH dependent and could affect proteolysis of the 
protein. 
 Schrader-Fischer et al. (1996) investigated the effect of alkalising agents on the 
processing of APP in HEK293 cells and showed that, when cells were treated with ammonium 
chloride(which raise extracellular pH), amyloidogenic processing of APP was inhibited, 
suggesting a possible inhibition of BACE1. However, it should be noted that the same report 
showed that chloroquine and bafilomycin (which have a similar effect on pH) did not alter 
BACE1 activity in the same manner. 
Collectively, these studies suggest that pH reductions promote amyloidogenic APP 
processing and provide evidence supporting the theory that alkalising agents, such as DCA, 
might impair these processes through a simple change in pH. 
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1.5.2.  Altered p53 levels as a potential mechanism by which DCA regulates APP 
proteolysis. 
 The p53 protein, otherwise known as the “guardian of the genome”, is a  
tumour-suppressing transcription factor which protects cells against uncontrolled division. 
Upon detection of stress, p53 transcriptionally activates various genes involved in cell cycle 
control and induces cycle arrest, DNA repair or apoptosis (Chira et al., 2018; Labuschagne, 
Zani and Vousden, 2018).  Over 50 % of cancers contain a mutation within the TP53 gene, 
allowing cells to divide uncontrollably and evade cell death (Sabapathy and Lane, 2018). The 
function of the p53 protein has, therefore, been extensively investigated in this context. The 
expression of p53 has also been shown to be regulated by DCA (Agnoletto et al., 2014) and to 
be regulated by APP proteolysis (Alves Da Costa et al., 2006). Therefore, it is possible that 
there may be links between altered p53 levels and the ability of DCA to regulate APP 
proteolysis. 
An increase in p53 levels, potentially leading to an increase in apoptosis and loss of 
neuronal cells, has been demonstrated in AD-afflicted brain tissues (Ganju et al., 1998; Ohyagi 
et al., 2005; Checler et al., 2011). However, the direct link between p53 and APP processing 
is currently not fully understood. 
Alves da Costa et al. (2006) demonstrated that the inhibition of γ-secretase function 
in various cells resulted in a significant reduction in p53 transcription, expression and 
function. The authors also showed that cells transfected with AICD displayed an increase in 
p53 transcription and function, and that APP knockout mice had lower brain p53 levels. 
Collectively, this study suggested that the AICD generated from APP CTFs by γ-secretase 
activity enhanced TP53 promoter activity leading to increased p53 protein expression.  
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 Whilst the preceding studies imply that APP can regulate p53 levels, it has also been 
shown that the latter protein can regulate the expression of the former. Cuesta et al. (2009) 
showed that increasing p53 expression and function led to a decrease in APP expression in 
murine N2a neuroblastoma cells. The authors went on to suggest that p53 prevented the 
binding of transcription factor Sp1 to the APP promotor, thereby impairing transcription of 
the gene. More recently, it has also been suggested that p53 may be able to regulate 
members of the γ-secretase complex (Checler et al., 2010), which may, therefore, alter the 
processing of APP.  
 
1.5.3.  Altered metabolite levels as potential mechanisms by which DCA regulates 
APP proteolysis. 
 The indirect activation of the PDH by DCA is likely to have a significant impact on the 
levels of various cellular metabolites, not least lactic acid and pyruvate. We, therefore, 
hypothesised that the supplementation of cell cultures with these metabolites, or the 
inhibition of enzymes involved in their metabolism, might be able to mimic the effects of DCA 
on APP proteolysis. The background relating to this hypothesis is discussed in the following 
sections. 
 
1.5.3.1. Lactate Dehydrogenase. 
  Initially, we sought to determine whether manipulating cellular levels of pyruvate or 
lactate through inhibition of lactate dehydrogenase (LDH) might mimic the effects of DCA on 
APP expression/proteolysis.  
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LDH is a vital enzyme involved in the reversible conversion of pyruvate to lactate in 
the glycolytic pathway (Fig. 1.7.). This enzyme is composed of two different monomers (A and 
B) which combine to form five different tetramers (LDH1–5), each with different properties 
and compositions of A and B monomers (Ding et al., 2017). LDH-B, which is predominantly 
expressed in the heart, is thought to be responsible for the conversion of lactate to pyruvate 
(as it has a higher affinity for the former compound) (Dawson et al., 1964). Conversely,  
LDH-A is highly expressed in skeletal muscle and has a higher affinity for pyruvate. Therefore, 
this monomer is thought to catalyse the conversion of pyruvate into lactate (Dawson et al., 
1964). 
 A link between the action of LDH and AD has been suggested following findings that 
neuronal cells with higher LDH function are resistant to Aβ (Soucek et al., 2003). The most 
resistant cells showed a greater reliance on glucose availability, suggesting that the resistance 
to Aβ toxicity was due to reduced reliance on aerobic respiration. Furthermore, the brains of 
AD patients demonstrate increased LDH-A activity and increased PDK activity relative to age-
matched controls (Bigl et al., 1999). 
 
1.5.3.2. Pyruvate. 
 We hypothesised that DCA might alter APP processing by reducing the pool of 
intracellular pyruvate levels due to the activation of the PDH (Fig. 1.7.). No previous studies 
have investigated how pyruvate may alter APP proteolysis, but the compound has been 
shown to protect neuronal cells against Aβ-induced toxicity in several studies (Alvarez et al., 
2003; Wang et al., 2011). 
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1.5.3.3. Lactic acid. 
   Given that DCA promotes the conversion of pyruvate to acetyl-coA, and that the 
former compound is used to generate lactic acid (Fig. 1.7.), it was possible that DCA might 
mediate APP processing by reducing the intracellular pool of lactic acid. 
 Lactic acid has previously been shown to enhance levels of Aβ and lower sAPPα 
production in SH-SY5Y cell cultures (Xiang et al., 2010). The authors also showed that  
full-length APP levels increased following lactic acid treatment and the protein exhibited an 
abnormal interaction with ER-chaperones, binding to glucose-regulated protein 78 (Grp78). 
It was suggested that this unusual binding led to an increased retention of APP in the ER/Golgi, 
enhanced co-localisation of APP and BACE1 and, therefore, an increased generation of Aβ and 
reduction of sAPPα production. Conversely, other studies have demonstrated a significant 
decrease in Aβ production following APP-Grp78 interaction (Yang et al., 1998; Kudo et al., 
2006). It has also been suggested that excessive production of lactic acid may enhance the 
activity of BACE1 by lowering pH of the brain and cerebral spinal fluid, potentially influencing 
APP amyloidogenic processing and the production of Aβ (Xiang et al., 2010). 
 
1.5.4.  Altered APP subcellular localisation as a potential mechanism by which DCA 
regulates APP proteolysis. 
 Given that the proteolysis of APP via the amyloidogenic and non-amyloidogenic 
pathways occurs in different subcellular impartments (discussed below), we hypothesised 
that DCA might exert its influence on APP processing by altering the subcellular distribution 
of the APP substrate protein. 
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It is widely accepted that APP is synthesised within membrane-bound polysomes 
before post-translational alterations (such as glycosylation, phosphorylation and 
sulphonation) within the ER and Golgi (Fig. 1.8.). Mature APP is then transported to either the 
cell surface (10 %) or remains within the TGN (90 %) (Plácido et al., 2014; Zhang et al., 2016; 
Toh et al., 2017). 
 APP is subject to non-amyloidogenic processing at the plasma membrane (Jiang et al., 
2014). APP which is not shed from the plasma membrane is then rapidly reinternalised, where 
it is either returned to the TGN, broken down in the lysosome or recycled back to the PM (Fig. 
1.8.). The precise location of amyloidogenic processing, however, is still under debate. 
Numerous studies have shown that it predominantly occurs following reinternalisation into 
the cell, either within the ER and Golgi complex, endosomal compartments or the TGN (Cook 
et al., 1997; Greenfield et al., 1999; Huse et al., 2002; Kaether et al., 2006). 
 
Figure 1.8. The intracellular processing of APP. (1) Initially, APP is transported to the PM, whilst undergoing 
posttranslational modifications. (2) The APP which is not released from the PM is reinternalised and sorted. (3) 
It is then either degraded in the lysosome, transported to the TGN or returned to the PM via recycling 
endosomes. (Image adapted from Haass et al., 2012). 
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 The findings that non-amyloidogenic and amyloidogenic APP processing occur in 
distinct subcellular compartments have led to several studies investigating how altering the 
subcellular localisation of the protein impacts on its processing. Perez et al. (1999) showed 
that inhibiting APP reinternalisation in Chinese hamster ovary (CHO) cells by mutating the APP 
C-terminal motif required for reinternalisation, led to reduced Aβ production due to a 
reduced interaction between APP and BACE1. Similarly, Carey et al. (2005) inhibited APP 
endocytosis in HEK293 cells by transfection with a dominant negative mutation within 
dynamin I and saw a decrease in Aβ formation. The influence of APP location on the 
processing of the protein was also investigated in HEK293 cells by Choy et al. (2012), who 
identified that retention of APP within the early endosomes, by depleting trafficking proteins 
Hrs and Tsg101 through shRNA treatments, led to a decrease in amyloidogenic processing. 
Additionally, the authors identified that retention of APP within the TGN, by depleting ESCRT 
subunit trafficking proteins CHMP6 and VPS4A/B through shRNA treatments, led to an 
increase in amyloidogenic processing. Furthermore, it has been identified that adaptor 
protein X11-deficient mice have an increase in APP and BACE1 colocalisation and an increase 
in Aβ production (Sano et al., 2006). The adaptor protein X11 usually binds to APP in the  
C-terminal region and retains it within detergent-sensitive membranes which are devoid of 
BACE1 (Sun and Roy, 2018). Therefore, this ultimately demonstrates that the correct 
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1.5.5.  Mitochondrial autophagy as a potential mechanism by which DCA regulates 
APP proteolysis.  
 In a recent study by Pajuelo-Reguera et al. (2015), DCA was shown to stimulate 
mitophagy in a dose-dependent manner and to alter the mitochondrial network morphology 
in SH-SY5Y cells. As such we hypothesised that, in the context of the current study, DCA might 
exert its influence on APP expression/proteolysis through similar alterations in the 
mitochondrial network. 
Mitochondria are preserved via a specific form of autophagy, called mitophagy, 
through which abnormal or damaged mitochondria are engulfed by autophagosomes and 
compartmentalised. These mitochondria are then broken down when lysosomes fuse with 
the compartment (Pajuelo-Reguera et al., 2015). This process is highly selective and tightly 
controlled to ensure that the correct mitochondria are degraded.  
Cole et al. (1989) previously showed that the inhibition of lysosomal enzymes and, 
therefore, mitophagy using ammonium chloride and leupeptin in a pheochromocytoma cell 
line (PC12) led to reduced Aβ production. This was additionally supported by Siman et al. 
(1993) who inhibited mitophagy using a variety of inhibitors (including ammonium chloride, 
chloroquine, E64, or Z-Phe-Ala-CHN2) in HCT293 cells overexpressing APP, also identifying a 
reduction in APP processing. This, therefore, suggests that inhibition of mitophagy also 
inhibits APP proteolysis (Salminen et al., 2013). However, many studies suggest that Aβ 
accumulation leads to mitochondrial damage and mitophagy, rather than suggesting that 
mitochondrial damage alters amyloidogenic processing. For example, Cha et al. (2012) 
showed that, when the immortalised mouse hippocampal neuronal cell line HT22 was treated 
with exogenous Aβ, there was a significant change in both the activity and morphology of 
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mitochondria. Similar results have also been shown in several other APP overexpression 
studies using M17 neuroblastoma cells and transgenic mice (Wang et al., 2008; Wu et al., 
2014). Furthermore, the morphology of mitochondria has been shown to be highly altered in 
AD-afflicted brain tissue (Trimmer and Borland, 2005). 
 The detrimental effect of Aβ aggregation on mitochondrial morphology has also been 
shown to contribute to the pathogenesis of AD. Firstly, Chen et al. (2007) showed that the 
loss of mitochondrial fusion resulted in poor mitochondrial dynamics and neurodegeneration. 
Mitochondrial fusion involves the integration of discrete, individual mitochondrion to form a 
single organelle, used to overcome stress-induced damage. This study used a mouse model 
with conditionally inactivated alleles of Mfn1 and Mfn2 (ATPases involved in fusion) and 
showed an associated increase in neurodegeneration. 
 Two other studies (Manczak et al., 2006; Petersen et al., 2008) also suggested that the 
neurotoxicity observed in AD-afflicted brains is partly due to the impact of Aβ accumulation 
upon mitochondrial function in that the peptides prevented proteins within the cytoplasm, 
for example the β-subunit of the F1-ATPase precursor protein, from entering the 
mitochondrial matrix. The authors found that this inhibition led to impaired electron 
transport chain function and increases in ROS production and oxidative DNA damage 
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1.5.6. Oxidative stress as a potential mechanism by which DCA regulates APP 
 proteolysis. 
 There are numerous publications relating to the role of oxidative stress in AD and 
these have been reviewed recently in Cheignon et al. (2018) and Chen and Zhong (2014). Of 
particular relevance to the current study are those publications which relate directly to the 
effect of oxidative stress on secretase-mediated proteolysis of APP. 
 It has recently been demonstrated that oxidative stress enhances the levels of BACE1 
expression, thereby enhancing amyloidogenic processing (Arimon et al., 2015). For example, 
in a study by Mouton Liger et al. (2012), SH-SY5Y cells were subjected to oxidative stress 
through hydrogen peroxide treatment and the levels of BACE1 dramatically increased. 
Furthermore, in a study by Guglielmotto et al. (2009), ischaemic rats were shown to have 
increased BACE1 expression and ROS production. The link between ROS and the altered 
BACE1 expression was then confirmed in a second experiment where ischaemic rats treated 
with antioxidants SOD/Cat and α-tocopherol, which prevented ROS production, where shown 
not to exhibit the same increases in BACE1. Additionally, in a study by Muche et al. (2017), 
oxidative stress was shown to enhance sAPPβ production in primary endothelial cells 
following hydrogen peroxide treatment. Taken together, these results suggest that oxidative 
stress enhances BACE1 production and leads to an increase in amyloidogenic processing.  
 Similar observations were also seen in a study by Kanamaru et al. (2015) who 
developed mice with enhanced oxidative stress due to a dominant-negative mutation within 
the mitochondrial aldehyde dehydrogenase 2. These mice exhibited increased Aβ deposition 
and decreased cognitive function, further suggesting that oxidative stress levels play a 
fundamental role in AD development. Tamagno et al. (2008) also demonstrated increased  
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γ-secretase and β-secretase levels in SK-N-BE neuroblastoma cells treated with the oxidative 
stress enhancers, 4-hydroxynonenal and H202. 
 Oxidative stress can also lead to peroxidation of lipids (Cheignon et al., 2018). These 
lipids are thought to contribute to the progression of AD as they have been shown to 
upregulate the production of BACE1 (Chen et al., 2008). This study found that, when 
glutathione peroxidase 4 (Gpx4) (which usually protects against lipid peroxidation) was 
knocked out in mice through a targeted mutation in the Gpx4 gene, there was a dramatic 
increase in BACE1 expression and Aβ aggregation. 
 Nuclear factor-κB (NF-κb), a protein which is activated by oxidative stress and ROS, 
has also been linked to BACE1 expression and amyloidogenic proteolysis of APP. Chen et al. 
(2012) found that various types of neuroblastoma cells transfected with NF-κB had enhanced 
expression of BACE1 due to enhanced promotor activity and, therefore, displayed increased 
amyloidogenic proteolysis. Additionally, the authors demonstrated that the frontal cortex of 
AD patients exhibited a significant increase in both NF-κB and BACE1 activity. 
 Furthermore, it has been suggested that Aβ production may lead to an increase in 
oxidative stress, which further enhances Aβ production, resulting in a positive feedback cycle 
(Smith et al., 2007). For example, Sheng et al. (2009) demonstrated significant reductions in 
both Aβ production and oxidative stress in mouse N2a neuroblastoma cells following 
inhibition of γ-secretase by expression of loss-of-function PS1 mutant D385A. 
 As previously discussed in section 1.4.1., DCA enhances oxidative stress and 
production of ROS. Therefore, as there is clearly a link between oxidative stress and APP 
proteolysis, it was hypothesised, in the current study, that this may be the mechanism by 
which DCA mediates APP processing. 
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1.6.  Project Aims. 
 The overarching aim of the current project was to identify the molecular mechanisms 
whereby dichloroacetate regulates APP proteolysis. In this respect, the effects of 
manipulating pH, p53 expression, LDH activity, pyruvate and lactate levels, mitochondrial 
autophagy and oxidative stress were all investigated in terms of their abilities to impact on 
APP expression and proteolysis. Furthermore, we also investigated the potential effects of 
DCA on the subcellular localisation of APP and the activity of BACE1. 
 Whilst the concentrations of DCA required to alter APP proteolysis might well be too 
high to make the drug a viable treatment for the disease, studies such as this into the cellular 
mechanisms whereby the drug effects such changes may well open avenues for the 
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2. Materials and Methods. 
2.1. Materials. 
 Anti-β-actin mouse monoclonal, anti-APP C-terminal rabbit polyclonal and  
anti-amyloid-β WO-2 mouse monoclonal antibodies were purchased from Sigma-Aldrich Ltd 
(Poole, UK). Anti-sAPPβ rabbit polyclonal, anti-p53 mouse monoclonal, and anti-APP 6E10 
mouse monoclonal antibodies were purchased from Biolegend (San Diego, USA). Anti-APP  
N-terminal 22C11 antibody was purchased from Merck Millipore (Darmstadt, Germany).  
Anti-LAMP1 rabbit polyclonal, anti-GM-130 rabbit polyclonal and anti-RAB6A rabbit 
polyclonal antibodies were purchased from Abcam (Cambridge, UK). Secondary  
peroxidase-conjugated antibodies were purchased from Sigma-Aldrich Ltd (Poole, UK). 
Secondary AlexaFluor-conjugated antibodies were purchased from Abcam (Cambridge, UK). 
 All cell culture reagents were purchased from Lonza Ltd (Basel, Switzerland), except 
for foetal bovine serum (FBS) which was supplied by Fisher Scientific (Loughborough, UK).  
 Unless otherwise stated, all other reagents were from Sigma-Aldrich Ltd (Poole, UK). 
 
2.2. Methods. 
2.2.1.  Cell culture. 
 Human neuroblastoma SH-SY5Y cells were cultured at 37 °C and 5 % CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 4 mM L-glutamine, 25 mM glucose, 10 % (v/v) 
filter-sterilised FBS, 50 μg/ml streptomycin and 50 U/ml penicillin. For sub-culturing, 
confluent cells were washed with 2 ml trypsin (200 mg/l versene EDTA, 170,000 U Trypsin/l)  
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Table 2.1. Quantities of culture medium used to resuspend SH-SY5Y cell pellets prepared from an initial 




which was then replaced with a fresh 2 ml of trypsin and incubated for 5 min at 37 °C. After 
tapping the flask to ensure all cells had detached, 20 ml culture medium was added to 
neutralise the trypsin and the cells were pelleted in an Allegra X-22R centrifuge (Beckman 
Coulter Ltd, High Wycombe, UK) at 500 rpm for 3 min. Once pelleted, the supernatant was 
decanted and cells were resuspended and seeded as described in Table 2.1. 
 
2.2.2. Resurrecting and freezing cell lines. 
 In order to resurrect a cell line from liquid nitrogen, cells were thawed at 37 °C and 
transferred into a Falcon tube containing 20 ml of culture medium. After centrifuging for 3 
min at 500 rpm in an Allegra X-22R centrifuge, the supernatant was decanted, and the cells 
were resuspended and seeded as described in Table 2.1. 
 For freezing cells, a confluent T75 cm² flask was pelleted as previously described in 
section 2.2.1. The pellet was then resuspended in 1.5 ml of culture medium containing 10 % 
Resuspension 







in subculture (μl) 
Volume of culture 
medium added to 
subcultures (μl) 
1000 per subculture T75 cm² flask 1000 10000 
1000 per subculture T25 cm2  flask 1000 8000 
30000 total 6 well plate 100 3000 
30000 total 96 well plate 50 150 
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(v/v) dimethyl sulphoxide (DMSO) in a cryovial. This suspension was then frozen at -80 °C for 
at least 24 h, before being placed into liquid nitrogen for permanent storage.  
 
2.2.3. Cell treatments. 
 For the dichloroacetate (DCA) treatments, 0.3 g of sodium dichloroacetate (MW 
150.92) was dissolved in 5 ml UltraMEM and filter-sterilised, giving a stock solution of 
approximately 400 mM DCA. This meant that adding 500 µl stock to 10 ml UltraMEM gave a 
treatment concentration of approximately 20 mM and adding 250 μl stock (with an additional 
250 µl UltraMEM) gave a final treatment concentration of approximately 10 mM DCA. Further 
dilutions of the stock were performed in order to achieve lower DCA concentrations whilst 
still adding a total of 500 µl to each 10 ml culture. Control cells were incubated in a total of 
10.5 ml UltraMEM. 
 For the acetic acid treatments, 115 µl acetic acid (99.5 % solution; 17.4 M) was added 
to 4885 µl UltraMEM and filter-sterilised to give a final stock concentration of approximately 
400 mM. This meant that adding 500 µl stock to 10 ml UltraMEM gave a treatment 
concentration of 20 mM and adding 250 μl stock (with an additional 250 µl UltraMEM) gave 
a treatment concentration of 10 mM. 
 For the sodium acetate (MW = 82.034) treatments, 0.16406 g was dissolved in 5 ml 
UltraMEM and filter-sterilised to give a final stock concentration of approximately 400 mM. 
This meant that adding 500 µl stock to 10 ml UltraMEM gave a treatment concentration of 20 
mM and adding 250 μl stock (with an additional 250 µl UltraMEM) gave a treatment 
concentration of 10 mM. 
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 For the Reactivating p53 and Inducing Tumour Apoptosis (RITA) treatments, RITA 
(CAY10006426- Cambridge Bioscience; MW = 292.37) was obtained as a 10 mg lyophilised 
sample. DMSO (1369.86 µl) was added to this sample, giving a stock concentration of 25 mM. 
The stock (10 μl) was then added to 90 µl DMSO, to give a final stock concentration of 2.5 
mM. This meant that adding 10 µl of final stock on 10 ml UltraMem gave a treatment 
concentration of 25 µM, 4 µl of final stock gave a treatment concentration of 10 µM, and 2 µl 
of final stock gave a treatment concentration of 5 µM. This stock was then serially diluted 10-
fold, meaning that adding 2 µl of the first serial dilution gave a treatment concentration of 
0.5 μM and 2 µl of the second serial dilution gave a treatment concentration of 0.05 µM. 
 For the GSK2837808A lactate dehydrogenase inhibitor (Tocris, Abingdon, UK; MW = 
649.62) treatment, 10 mg of inhibitor was reconstituted in 30.5754 ml DMSO, which was then 
divided into 1 ml aliquots and frozen at -20 °C in order to give a 10 x stock. One of these 
aliquots was diluted 10-fold with DMSO to give 1 x stocks which were divided into 200 µl 
aliquots and frozen. When using 10 ml culture volumes, 10 µl of the 1 x stock was added to 
the medium to give a final inhibitor concentration of 50 nM. All other final concentrations 
were produced by further dilution of the 1 x stock with DMSO, prior to adding 10 µl of these 
dilutions to the cultures. For 96 well plate cultures containing 200 µl medium per well, the 1 
x stock was diluted 10-fold with DMSO and 2 µl of this was added to the wells to give a final 
inhibitor concentration of 50 nM. 
 For the FX11 lactate dehydrogenase inhibitor (Merck Millipore, Darmstadt, Germany; 
MW = 350) treatment, 10 mg FXII LDHA compound was dissolved in 285.71 µl DMSO, giving a 
stock concentration of 1 mM. This meant that adding 10 µl stock to 10 ml UltraMEM gave a 
final treatment concentration of 100 µM in T75 cm2 flasks. For all other inhibitor 
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concentrations, the stock was diluted such that the same volume (10 µl) could be added to 
cultures to give lower final inhibitor concentrations. For 96 well plate cultures containing 200 
µl of medium per well, the stock was diluted 10-fold with DMSO and 2 µl of this was added to 
each well to give a 100 µM final inhibitor concentration. 
 For the pyruvate treatments, it is worth noting initially that the basal concentration of 
pyruvate in UltraMEM is 1 mM. As such, the UltraMEM ‘control’ for these experiments 
actually represented 1 mM pyruvate and the mass calculations for all other pyruvate 
concentrations were performed taking this initial 1 mM concentration into account. As such, 
0.54648 g of sodium pyruvate (Sigma-Aldrich Ltd, Pool, UK; MW = 110.4) was dissolved in 50 
ml UltraMEM and filter-sterilised. Cells were cultured directly in this solution without any 
further dilution, such that the final pyruvate concentration was 100 mM. Other final pyruvate 
concentrations were obtained simply by adjusting the weight of dry powder dissolved in the 
UltraMEM in which the cells were cultured. 
 For the lactic acid treatments, 0.54048 g of lactic acid (Sigma-Aldrich Ltd, Poole, UK; 
MW = 90.08) was dissolved in 10 ml UltraMEM and filter-sterilised to give a final stock solution 
of 600 mM. This meant that adding 200 µl of stock solution to 10 ml UltraMEM gave a final 
treatment concentration of 12 mM. 
 For the N-acetyl cysteine (NAC) treatments, 0.163195 g NAC (Sigma-Aldrich Ltd, Poole, 
UK; MW = 163.195) was dissolved in 10 ml distilled water and filter-sterilised to give a final 
stock concentration of 100 mM. This meant that adding 100 µl of stock solution to 10 ml 
UltraMEM gave a final treatment concentration of 1 mM. 
 For the ammonium chloride treatments, 0.5349 g of ammonium chloride  
(Sigma-Aldrich Ltd, Poole, UK; MW = 53.49) was dissolved in 10 ml UltraMEM and  
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filter-sterilised to give a stock solution of 1 M. This meant that adding 100 µl of stock to 10 ml 
UltraMEM gave a final treatment concentration of 10 mM.  
 For the chloroquine diphosphate treatments, 0.25793 g of chloroquine diphosphate 
(Sigma-Aldrich Ltd, Poole, UK; MW = 515.86) was dissolved in 100 ml UltraMEM to give a final 
stock concentration of 5 mM. This meant that adding 100 µl of stock solution to 10 ml 
UltraMEM gave a final treatment concentration of 50 µM. 
 For the batimastat treatments, 10 mg batimastat (Biotechne, Abingdon, UK; MW = 
78.13) was dissolved in 12.7992 ml DMSO to give a stock solution of 10 mM. This meant that 
adding 5 µl to 10 ml UltraMEM gave a final treatment concentration of 5 µM. 
 
2.2.4. Small interfering RNA (siRNA) treatments. 
 siRNAs were obtained from Dharmacon (Cambridge, UK) and were as follows: 
Control siRNA: Cat. No. D-001810-10-05, ON-TARGETplus Non-Targeting Pool, (5 nM)  
p53 siRNA: Cat. No. J-003329-15-0020 On target plus siRNA (TP53 gene) (20 nM)  
The following method is based on the transfection of cells in a single well of a 6 well 
plate (with a surface area of 10 cm2) and will yield a final Dharmafect transfection reagent 
concentration of 5 µl/ml and a final siRNA concentration of 37.5 nM. If higher concentrations 
of either Dharmafect or siRNA were required, then the volumes of UltraMEM in tubes A and 
B were reduced accordingly. Similarly, for transfecting larger scale cell cultures, the volumes 
of all reagents were simply increased in a manner proportionate to the surface area of the 
culture vessel used. 
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The siRNAs supplied from the manufacturer were made up to 5 µM stocks using 
RNase-free water. Dharmafect (10 µl) was diluted with 190 µl of UltraMEM in Tube A and 
then 15 µl of siRNA stock was diluted with 185 µl of UltraMEM in Tube B. After incubating 
both tubes at room temperature for 5 min, the two tubes were combined and incubated for 
a further 20 min at the same temperature. Complete medium lacking antibiotic (1.6 ml) was 
then added to the mixture to make a total volume of 2 ml. The existing medium was removed 
from 70 % confluent cultures in 6 well plates and replaced with the 2 ml of transfection 
mixture described above. The cultures were then grown for a further 24 h before replacing 
the medium with 2 ml of normal (antibiotic containing) complete growth medium. Cultures 
were then grown for a further 48–72 h prior to drug treatments. 
 
2.2.5. Preparing conditioned medium and cell lysate samples. 
 Cell debris was removed from conditioned cell culture medium by centrifuging in a 
Rotana 460R centrifuge at 3000 rpm at 4 °C for 5 min. Amicon Ultra-4 centrifugal filters (Merck 
Millipore, Darmstadt, Germany) were equilibrated by spinning through 4 ml d.H2O for 10 min 
at 4000 rpm and 4 °C. Equilibrated filters were then used to concentrate 8 ml of medium 
supernatant to 250 μl for approximately 50 min at 3500 rpm and 4 °C.  
 In order to prepare cell lysates, cells were washed in situ with 10 ml  
phosphate-buffered saline (PBS; 0.15 M NaCl, 2 mM NaH2PO4, 2 mM Na2HPO4, pH 7.4). The 
cells were then covered with a fresh 10 ml PBS, scraped from the base of the flask and 
transferred into a Falcon tube. An additional 10 ml PBS was then used to wash the remaining 
cells from the flask into the same Falcon tube. The cells were pelleted at 1500 g for 3 min at 
4 °C. The cell pellet was resuspended in 1.5 ml of lysis buffer (50 mM Tris, 150 mM NaCl, 1 % 
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(v/v) Igepal, 0.1 % (w/v) sodium deoxycholate, 5 mM EDTA, pH 7.4) containing 1 % (v/v) 
protease inhibitor cocktail (1.04 mM AEBSF, 0.02 mM leupeptin, 0.8 μM Aprotinin, 0.04 mM 
Bestatin, 0.0014 mM E-64, and 0.015 mM pepstatin A) and sonicated for 30 s using a probe 
sonicator (MSE, Crawley, UK) set at half power. The sonicated sample (1 ml) was then 
transferred into an eppendorf and insoluble material was pelleted at 11,600 g for 10 min, 
before the supernatant was transferred into a new eppendorf and the pellet was discarded. 
Once the protein levels were assayed and equalised (section 2.2.6.), lysate samples were 
frozen at -80 °C in 150 μl aliquots. 
 
2.2.6. Bicinchoninic acid (BCA) protein assay. 
 Standard bovine serum albumin (BSA) concentrations were prepared at 
concentrations of 0, 0.2, 0.4, 0.6, 0.8, and 1 mg/ml. BSA standards (10 µl) and appropriate 
volumes of lysate samples were pipetted into a 96-well microtitre plate in duplicate. BCA 
protein assay reagent (Fisher Scientific, Loughborough, UK) and 4 % (w/v) CuSO4.5H20 were 
combined at a 50:1 volume ratio to produce the BCA assay working reagent, 200 μl of which 
was added to each well. Samples were then mixed by tapping the plate, before incubating at 
37 °C for 30 min. After sufficient colour development, the absorbance was read at 570 nm 
using a Victor2 1420 multilabel counter microplate reader (Lab Merchant Ltd, London, UK). 
The means of each pair of BSA standards were then used to generate a calibration curve which 
was used to determine the concentration of protein in each lysate sample. Concentrations of 
each sample were then equalised using lysis buffer containing 1 % (v/v) protease inhibitor 
cocktail. 
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2.2.7. Sodium dodecylsulphate – polyacrylamide gel electrophoresis (SDS-PAGE). 
 Stacking and resolving gel solutions were prepared as described in Table 2.2. 
Continuous gradient gels were poured using a mixing chamber and peristaltic pump. The 
resolving gel was covered with isobutanol and left to set for 30 min, following which the 
isobutanol was removed and the stacking gel was poured and left to set for a further 30 min. 
Samples were mixed with dissociation buffer (3.5 ml 1 M Tris/HCl pH 6.8, 2.5 g sodium 
dodecyl sulfate (SDS), 0.3085 g dithiothreitol (DTT), 5 ml glycerol, 16.5 ml d.H20, 0.05 g 
bromophenol blue) at a volume ratio of 2:1. Molecular weight markers standards (GE 
Healthcare Ltd, Hatfield, UK) were prepared in the same manner. All samples and standards 
were boiled at 100 °C for 3 min. Samples and MW standards (30 μl) were loaded and resolved 
at 35 mA per gel in running buffer (25 mM Tris, 192 mM glycine, 0.1 % (w/v) SDS; Scientific 
Laboratory Supplies Ltd, Nottingham, UK) until the loading dye reached the base of the gel. 
Table 2.2. Gel solution components.  
 7 % 17 % 5 % 20 % Stacking gel 
Sucrose - 0.37 g - 0.37 g - 
Distilled H20 1.36 ml - 1.44 ml - 7.65 ml 
1 M Tris/HCl, pH 8.8 1.39 ml 1.39 ml 1.39 ml - - 
1 M Tris/HCl, pH 6.8 - - - - 1.25 ml 
1.5 M Tris, pH 8.8  - - - 0.93 ml  
10 % (w/v) SDS 37 μl 37 μl 37 μl 37 μl 100 μl 
30 % acrylamide, 0.8 % Bis 0.88 ml 2.1 ml 2.5 ml 0.63 ml 1 ml 
1.5 % (w/v) ammonium persulfate 100 μl 220 μl 71 μl 220 μl 0.5 ml 
TEMED 3 μl 3 μl 3 μl 3 μl 10 μl 
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2.2.8. Immunoblotting. 
 Immobilon P polyvinylidene difluoride (PDVF) membrane (Merck Millipore, 
Darmstadt, Germany) was equilibrated in methanol for 10 s, d.H2O for 2 min and Towbin 
transfer buffer (800 ml methanol, 150 mM glycine, 20 mM Tris, 3200 ml d.H2O, pH 8.3) for 20 
min. Proteins were then transferred in Towbin buffer at 115 V for 60 min. The membrane was 
then washed in PBS for 5 min followed by blocking with 50 ml of 5 % (w/v) marvel in PBS 
containing 0.1 % (v/v) Tween 20 (PBS-Tween) for 60 min at RT. All RT incubations were 
performed on a rocking platform. The membranes were then washed in PBS for an additional 
5 min before incubating in primary antibody overnight at 4 °C on a roller mixer spiralizer 
(Stuart, Staffordshire, UK). Primary antibodies were prepared in 0.2 % (w/v) BSA in PBS-Tween 
at the dilutions shown in Table 2.3.  
 The next day, membranes were washed in PBS-Tween for 1 x 1 min and 2 x 15 min. 
Membranes were then incubated in secondary antibody for 60 min at RT. Secondary 
antibodies were prepared in 0.2 % (w/v) BSA in PBS-Tween at the concentrations shown in 
Table 2.3. This was then followed by washing in PBS for 1 x 1 min and 2 x 15 min.  
The blots were then developed with Enhanced Chemiluminescence reagent (ECL) 
(Fisher Scientific, Loughborough, UK). They were submerged in ECL reagent for 3 min, 
sandwiched between acetate sheets and exposed to CL-XPosure™ clear blue X-ray film (Fisher 
Scientific, Loughborough, UK). This was then developed manually using Carestream® Kodak® 
autoradiography GBX fixer and replenisher (Sigma-Aldrich, Poole, UK). 
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Table 2.3. Concentrations of antibodies used in Western blotting. 
 
2.2.9. Amido black staining of membranes. 
 Proteins on membranes were visualised using amido black stain (0.1 % (w/v) amido 
black, 1 % (v/v) acetic acid, 40 % (v/v) methanol). Membranes were then destained in tap 
water. 
 
2.2.10. Quantification of immunoblots. 
 X-ray films were scanned, and image files were imported in to ‘ImageJ’ quantification 
software. Images were converted to greyscale before the areas of bands were quantified. 
 
2.2.11. MTS 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo 
 phenyl)-2H-tetrazolium) cell viability assays. 
 MTS viability assays were performed in 96 well microtitre plates. Medium was 





APP-CT  1/5000 
22C11 1/5000 
sAPPβ 1/1000 
Rabbit anti-mouse 1/4000 
Goat anti-rabbit  1/4000 
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with a fresh 100 μl of UltraMEM before adding 20 µl of CellTiter 96® AQueous One Cell 
Proliferation Assay solution (Promega, Wisconsin, USA). Background control wells contained 
just UltraMEM and MTS reagent. The plate was covered in foil and incubated at 37 °C (with 
mixing every 2 min) until there was sufficient colour development. Absorbances were then 
read at 490 nm using a Victor2 1420 multilabel counter microplate reader (Lab Merchant Ltd, 
London, UK). 
 
2.2.12. Trypan Blue Assay. 
 Cells from cultures were trypsinised and pelleted as described in section 2.2.1. and 
resuspended in 15 ml of PBS. Cell suspension (20 µl) and trypan blue (20 µl) were combined 
and the solution was incubated for 2 min before placing 20 μl of this solution onto a 
haemocytometer and counting the cells. The cell counts in four large grids were averaged and 
multiplied by 400 to give the number of cells in 20 µl, and then by 750 to give the amount in 
15 ml. Finally, the amount was multiplied by 2, to account for the original 1:1 dilution with 
trypan blue. 
 
2.2.13. BACE1 activity fluorescence assay. 
  BACE1 activity in cell lysates was measured using the Fluorometric Beta Secretase 
Activity Kit (Abcam, Cambridge, UK) according to the manufacturer’s instructions. 
Fluorescence was read at 335/495 nm using an infinite M200 pro tecan plate reader (Tecan 
Trading, Männedorf, Switzerland). 
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2.2.14. Immunofluorescence microscopy.  
 Glass coverslips (24 mm²) were submerged in sterile 0.01 % (w/v) poly-L-lysine 
solution (Sigma-Aldrich Ltd., Poole, UK.) for 45 min on a rocking platform at RT, before being 
washed 10 times in d.H20. The coverslips were allowed to dry and then either stored at room 
temperature at this stage or the process was continued by rinsing them, under aseptic 
conditions, in absolute ethanol. After drying under aseptic conditions, each coverslip was then 
placed in an individual well of a 6 well plate. SH-SY5Y cells were seeded in growth medium 
lacking antibiotics as described in Table 2.1. Once the cells reached 60 % confluency, if 
required, they were treated with DCA or batimastat for 24 h as described in section 2.2.3. 
before being processed for immunofluorescence (below). 
 Paraformaldehyde (4% w/v) was prepared by heating 80 ml of PBS to 60 °C and, whilst 
stirring, adding 4 g of paraformaldehyde. The pH was then slowly increased by adding 1 M 
NaOH until the paraformaldehyde dissolved. The solution was then brought to 100 ml with 
PBS and the pH adjusted to 6.9. Once cooled, the solution was filter-sterilised before use. 
 Coverslips were transferred to the wells of a fresh 6 well plate and washed with 2.5 
ml ice-cold PBS which was then immediately  replaced with 2 ml of 4 % (w/v) 
paraformaldehyde and the cells were fixed for 30 min. The paraformaldehyde was then 
removed and the coverslips were washed 3 times in 2.5 ml ice-cold PBS. Following removal of 
the last wash solution, the cells were permeabilised by incubating in 2.5 ml of 0.1 % (v/v) 
Triton X-100 in PBS for 10 min at RT. The coverslips were then washed 3 times in 2.5 ml PBS 
for 5 min and then inverted on to 500 µl of 5 % (v/v) goat serum in PBS containing 0.1 % Tween 
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for 1 h at RT on parafilm. Coverslips were then transferred to fresh 6-well plates and washed 
3 times for 5 min in 2.5 ml PBS.  
 Primary antibodies (Table 2.4.) were made up in 100 µl of 5 % (v/v) goat serum in  
PBS-0.1 % (v/v) Tween. Following the final PBS wash, coverslips were removed from the 6 well 
plates and placed, cell side up, on parafilm squares. The primary antibodies were then placed 
on the coverslips and covered with another parafilm square to ensure even distribution of the 
antibodies. Primary antibody incubations were conducted for 1 h at RT after which the 
coverslips were transferred back into 6 well plates and washed 3 times with 2.5 ml PBS for 5 
min. Secondary fluorophore-conjugated antibody incubations (Table 2.4.) were performed as 
described above in relation to the primary antibodies except that the incubations were 
performed in the dark. The coverslips were then transferred back into 6 well plates and 
washed 3 x 5 min in the dark with 2.5 ml PBS. Before being mounted on to slides, the 
coverslips were dipped briefly in to distilled water to remove excess salt and then the edges 
of the slides were blotted in order to remove excess liquid. Finally, the coverslips were 
inverted on to two drops of Vectashield (containing DAPI; Vectorlabs, Peterborough, UK) on 
slides and allowed to set for 30 min at RT before storing at -80 °C in the dark. Slides were 
visualised using a Zeiss LSM880 Laser scanning confocal microscope (Zeiss, Denmark).  
Table 2.4. Concentrations of antibodies used in immunofluorescence microscopy. 
 
Antibody Concentration 
Anti-amyloid beta WO-2 1/50 
Anti-LAMP1  1/140 
Anti-RAB6A 1/100 
Anti-GM-130 1/200 
Goat-anti mouse IgG H+L (AlexaFluor 488) preabsorbed 1/200 
Goat-anti mouse IgG H+L (AlexaFluor 594) preabsorbed 1/200 
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2.2.15. Statistical analysis. 
 Microsoft Excel was used to perform unpaired, two-tailed homoscedastic student’s t-
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3. The role of pH in the DCA-mediated regulation of APP proteolysis.  
In order to examine the mechanism by which DCA regulates APP proteolysis, it was 
first necessary to characterise the effects of the compound on the endogenous protein in the 
human neuroblastoma cell line, SH-SY5Y. It was then hypothesised that a simple change in 
cell culture medium pH mediated by DCA might alter APP processing. To this end,  
structurally-related compounds which also altered pH were tested in terms of their abilities 
to alter APP expression and/or proteolysis. 
 
3.1. The effect of different DCA treatment regimes on APP proteolysis. 
In order to subsequently examine the mechanism of DCA in the regulation of APP 
proteolysis, the effects of the compound on the endogenous protein in the human 
neuroblastoma cell line, SH-SY5Y, were characterised over different treatment regimes (24 h 
and extended time course treatments). 
 
3.1.1. 24 h DCA treatment regime. 
Cells were initially grown to confluence and treated for 24 h with UltraMEM containing 
DCA. Cells and medium were subsequently harvested and analysed, as described in the 
Materials and Methods section, in order to determine the effects of DCA on cell viability and 
APP expression/proteolysis. 
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The cell viability results (Fig. 3.1.) showed that, when using the MTS assay as a means 
of assessing viability, there were no changes in viable cell number when the cells were treated 
with DCA for 24 h. The situation was similar when using trypan blue, although this method 
showed a slight but significant decrease in viable cell number when cultures were treated for 




Figure 3.1. The effect of 24 h DCA treatment on SH-SY5Y cell viability. SH-SY5Y cells were treated with DCA at 
the concentrations indicated for 24 h. Cells were either trypsinised and counted via trypan blue or quantified 
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When lysates from cells treated for 24 h with 10 mM DCA were immunoblotted with 
the anti-APP C-terminal antibody (Fig. 3.2.), no significant change in full-length APP expression 
was observed. However, when cells were treated with 20 mM DCA, a significant increase in 




Figure 3.2. The effect of 24 h DCA treatment on the expression of full-length APP in SH-SY5Y cells. SH-SY5Y 
cells were treated with DCA at the concentrations indicated for 24 h. Equal amounts of lysate protein were then 
immunoblotted with (A) anti-APP C-terminal and (B) anti-actin antibodies. Results are means ± S.D. (n=3). 
Significant results are indicated: * = significant at p ≤ 0.05. 
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 When 24 h DCA-treated cell lysates were immunoblotted with anti-p53 antibody (Fig. 
3.3.), significant increases in p53 levels were observed with both 10 and 20 mM DCA 
treatments (113.71 ± 36.37 and 228.74 ± 32.89 % increases, respectively, relative to controls). 
 
Figure 3.3. The effect of 24 h DCA treatment on the levels of p53 in SH-SY5Y cells. SH-SY5Y cells were treated 
with DCA at the concentrations indicated for 24 h. Equal amounts of lysate protein were then immunoblotted 
with anti-p53 antibody. Results are means ± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 
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Next, the effects of 24 h DCA treatment on the levels of sAPPα and sAPPβ production 
in conditioned medium were examined. To detect the former fragment, concentrated 
conditioned medium was first immunoblotted with the anti-APP 6E10 antibody. The results 
(Fig. 3.4.) revealed that, when cells were treated with 10 mM DCA, there were significant 
increases in both sAPP695α and sAPP751/770α levels in the medium (114.00 ± 34.40 and 
267.23 ± 94.83 % increases, respectively, relative to controls). Cells treated with 20 mM DCA 
also generated more of both sAPP695α and sAPP751/770α (216.93 ± 9.85 and 396.25 ± 32.40 
% increases, respectively, relative to controls).  
 
Figure 3.4. The effect of 24 h DCA treatment on the production of sAPPα by SH-SY5Y cells. SH-SY5Y cells were 
treated with DCA at the concentrations indicated for 24 h. Equal volumes of concentrated medium were then 
immunoblotted with the anti-sAPPα 6E10 antibody. Results are means ± S.D. (n=3).  Significant results are 
indicated: * = significant at p ≤ 0.05, *** = significant at p ≤ 0.005, **** = significant at p ≤ 0.001.  
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When medium from 24 h DCA-treated cells was immunoblotted with the anti-sAPPβ 
antibody, the results (Fig. 3.5.) revealed that culture treatments of 10 and 20 mM DCA both 
led to a significant decrease in sAPPβ production, relative to control cultures (45.37 ± 6.98 
and 60.63 ± 10.31 % reductions, respectively). 
 
 
Figure 3.5. The effect of 24 h DCA treatment on the production of sAPPβ by SH-SY5Y cells. SH-SY5Y cells were 
treated with DCA at the concentrations indicated for 24 h. Equal volumes of concentrated medium were then 
immunoblotted with the anti-sAPPβ antibody. Results are means ± S.D. (n=3). Significant results are indicated: 
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3.1.2.  Extended time course DCA treatment regime. 
Previously, only two DCA concentrations (10 and 20 mM) had been investigated in 
terms of the ability of the drug to alter APP proteolysis over a 24 h period. In order to 
determine whether cells could be grown effectively in the presence of DCA and to examine 
whether lower concentrations of the compound could alter APP proteolysis, the effects of 
long-term DCA exposure on APP expression/proteolysis in SH-SY5Y cells were characterised. 
Here, cells were seeded and cultured in the presence of 0, 0.1, 1 or 10 mM DCA (as opposed 
to growing them to confluence before treatment) for 3 passages. Once each set of cells had 
reached confluency following the third passage, the DCA-containing growth medium was 
replaced with UltraMEM containing the same drug concentrations. The cells were then 
cultured for a further 24 h, after which lysates and concentrated conditioned medium 
samples were prepared as described in the Materials and Methods section. 
When extended time course DCA-treated cell lysates were immunoblotted with the 
anti-APP C-terminal antibody (Fig. 3.6.), no significant increases in full-length APP expression 
were observed in either 0.1 or 1 mM DCA treated cells. Cells treated with 10 mM DCA, 
however, exhibited a significant increase in full-length APP expression (114.28 ± 24.27 % 
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Figure 3.6. The effect of extended time course DCA treatment on full-length APP expression. SH-SY5Y cells 
were cultured in the presence of the indicated DCA concentrations for 3 passages, before a final 24 h treatment 
with DCA in UltraMEM. Equal amounts of lysate protein were then immunoblotted with (A) anti-APP C-terminal 
and (B) anti-actin antibodies. Results are means ± S.D. (n=3). Significant results are indicated: * = significant at p 
≤ 0.05.  
 
When the same cell lysates were immunoblotted with anti-p53 antibody (Fig. 3.7.), no 
significant increases in p53 levels were observed in either 0.1 or 1 mM DCA-treated cells. 
However, cells treated with 10 mM DCA saw a significant increase in p53 levels of 142.51 ± 
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Figure 3.7. The effect of extended time course DCA treatment on p53 levels. SH-SY5Y cells were cultured in the 
presence of the indicated DCA concentrations for 3 passages, before a final 24 h treatment with DCA in 
UltraMEM. Equal amounts of lysate protein were then immunoblotted with anti-p53 antibody. Results are 
means ± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05. 
 
Next, the effects of extended time course DCA treatment on the generation of sAPPα 
and sAPPβ by SH-SY5Y cells were examined. When the concentrated conditioned medium 
from the final 24 h UltraMEM incubation was immunoblotted with anti-APP 6E10 antibody, 
the results (Fig. 3.8.) revealed that cells treated with 0.1, 1 and 10 mM DCA all generated 
significantly more sAPPα compared to control cells (20.41 ± 6.04, 38.58 ± 17.16, and 58.47 ± 
28.93 % increases, respectively, relative to controls). 
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Figure 3.8. The effect of extended time course DCA treatment on sAPPα production by SH-SY5Y cells. Cells 
were cultured in the presence of the indicated DCA concentrations for 3 passages, before a final 24 h treatment 
with DCA in UltraMEM. Equal volumes of this final concentrated conditioned medium were then immunoblotted 
with the anti-sAPPα 6E10 antibody. Results are means ± S.D. (n=3). Significant results are indicated: * = 
significant at p ≤ 0.05. 
 
When the same medium was immunoblotted with the anti-sAPPβ antibody, the 
results (Fig. 3.9.) actually showed a significant increase in the generation of this fragment by 
cells cultured in the presence of the lowest (0.1 mM) concentration of DCA (26.24 ± 5.51 % 
increase, relative to controls). However, at the previously studied 10 mM concentration, the 
amount of sAPPβgenerated was, as previously observed, decreased relative to control 




- 59 - 
 
 
Figure 3.9. The effect of extended time course DCA treatment on sAPPβ production by SH-SY5Y cells. Cells 
were cultured in the presence of the indicated DCA concentrations for 3 passages, before a final 24 h treatment 
with DCA in UltraMEM. Equal volumes of this final concentrated conditioned medium were then immunoblotted 
with the anti-sAPPβ antibody. Results are means ± S.D. (n=3). Significant results are indicated: * = significant at 
p ≤ 0.05. 
 
 
3.2. The effect of pH altering compounds structurally related to DCA on APP 
expression/proteolysis. 
 Having established that either short-term (24 h) or chronic exposure to DCA enhanced 
non-amyloidogenic and decreased the amyloidogenic processing of APP in SH-SY5Y cells, it 
was hypothesised that these effects might be mediated by simple changes in medium pH 
brought about by the drug. As such, the pH of the conditioned medium from 24 h DCA-treated 
cells was initially examined. The results (Fig. 3.10.) showed a significant increase in the pH of 
conditioned medium from cells treated with both 10 and 20 mM DCA, with the pH of control 
cultures being 6.96 ± 0.09 and that in the 10 and 20 mM DCA-treated cultures being 7.14 ± 
0.03 and 7.23 ± 0.01, respectively. 
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Figure 3.10. The effect of 24 h DCA treatment on the pH of conditioned medium. SH-SY5Y cells were treated 
with DCA at the concentrations indicated in UltraMEM for 24 h before measuring the pH of the medium. Results 
are means ± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05. 
 
 
 Given that DCA significantly enhanced the pH of the conditioned medium at the same 
drug concentrations as those which impacted on APP expression/proteolysis, it was then 
decided to investigate the effects of structurally related pH altering compounds on pH, cell 
viability and APP expression/proteolysis. 
 
3.2.1.  Sodium acetate. 
 In order to compare any potential effects of sodium acetate on APP 
expression/proteolysis to those mediated by sodium DCA (structures shown in Fig. 3.11.), SH-
SY5Y cells were grown to confluence and treated for 24 h with UltraMEM containing molar 
concentrations of sodium acetate equivalent to those previously employed with DCA. Cells 
and medium were subsequently harvested, processed and analysed, as described in the 
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Materials and Methods section. Prior to concentrating, the pH of the conditioned medium 
was analysed. The results (Fig. 3.12.), similar to those observed with DCA (Fig. 3.10.), showed 
a significant increase in the pH of medium containing sodium acetate. Here, the pH of the 
medium from control cultures was 7.00 ± 0.03 and increased to 7.11 ± 0.02 and 7.19 ± 0.03, 





Figure 3.11. The structures of sodium dichloroacetate (A) and sodium acetate (B). 
 
 
Figure 3.12. The effect of 24 h sodium acetate treatment on the pH of conditioned medium. SH-SY5Y cells were 
treated with sodium acetate at the concentrations indicated in UltraMEM for 24 h before measuring the pH of 
the medium. Results are means ± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05, *** = 
significant at p ≤ 0.005. 
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 Given that sodium acetate had an almost identical effect on the pH of conditioned 
medium to that of DCA, the viability of SH-SY5Y cells treated with the former compound was 
also investigated using the MTS assay, as described in the Materials and Methods section. The 
results (Fig. 3.13.) showed that whilst there was no significant effect of 10 mM sodium acetate 
on viability, there was a significant decrease of 16.92 ± 3.73 %, relative to control cultures, in 
the viability of 20 mM compound-treated cells. Hence, as with DCA, only relatively minor 
effects on cell viability were observed in sodium acetate-treated cultures. 
 
 
Figure 3.13. The effect of 24 h sodium acetate treatment on the viability of SH-SY5Y cells. Cells were treated 
with sodium acetate at the concentrations indicated for 24 h. Cell viability was then assessed through an MTS 
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Next, the effects of 24 h sodium acetate treatment on the expression of APP and p53 
and proteolysis of the former protein were examined. To this end, lysates prepared from 
drug-treated cells were firstly immunoblotted with the anti-APP C-terminal antibody. The 
results (Fig. 3.14.) revealed no significant differences in the expression of full-length APP 
following the treatment of cells with sodium acetate (in contrast to clear increases observed 
previously with DCA).  
 
Figure 3.14. The effect of sodium acetate treatment on full-length APP expression. SH-SY5Y cells were cultured 
in the presence of the indicated sodium acetate concentrations in UltraMEM for 24 h. Equal amounts of lysate 
protein were then immunoblotted with (A) anti-APP C-terminal and (B) anti-actin antibodies. Results are means 
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When 24 h sodium acetate-treated cell lysates were immunoblotted with anti-p53 
antibody (Fig. 3.15.), the results revealed a 68.89 ± 8.11 % decrease in the levels of this protein 
in 20 mM drug-treated cell lysates, relative to controls. Interestingly, despite the pH changes 
induced by sodium acetate being similar to those affected by DCA, the effect of the former 
compound on p53 levels was the complete opposite to that of DCA (which enhanced p53 
levels).  
 
Figure 3.15. The effect of sodium acetate treatment on p53 levels. SH-SY5Y cells were cultured in the presence 
of the indicated sodium acetate concentrations in UltraMEM for 24 h. Equal amounts of lysate protein were 
then immunoblotted with anti-p53 antibody. Results are means ± S.D. (n=3). Significant results are indicated: 
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Next, conditioned medium from the 24 h sodium acetate-treated cells was 
immunoblotted with the anti-APP 6E10 antibody to detect sAPPα Initially, the results were 
quantified in terms of the absolute amount of the protein fragment released by cells (Fig. 
3.16A.). Here, cells treated with 10 mM sodium acetate demonstrated a 34.40 ± 9.68 % 
increase specifically in the generation of sAPP695α but this difference was not significant at 
a 20 mM compound concentration. Conversely, although levels of sAPP751/770α appeared 
to increase at both sodium acetate concentrations, the increase was only significant at 20 mM 
(34.40 ± 9.68 % increase relative to controls). The results were also standardised to account 
for the minor decreases observed in cell viability previously in Fig. 3.14. These latter results 
(Fig. 3.16B.) gave similar results but with higher levels of significance. As such, like DCA, 
sodium acetate appears to enhance sAPPα generation. 
 The same conditioned medium samples were then immunoblotted for sAPPβ and the 
results (Fig. 3.17) clearly showed a significant increase in sAPPβ generation by sodium 
acetate-treated cells. Non-standardised results (Fig. 3.17A.) revealed 24.50 ± 7.96 and 44.27 
± 14.72 % increases in 10 and 20 mM sodium acetate-treated cultures, respectively. When 
these results were corrected to account for changes in cell viability (Fig. 3.17B.) these 
differences were even more apparent. It is of note that, despite having similar effects on cell 
viability and sAPPα generation to DCA, sodium acetate increased rather than decreased 
sAPPβ generation. 
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Figure 3.16. The effect of 24 h sodium acetate treatment on the production of sAPPα by SH-SY5Y cells. Cells 
were treated with sodium acetate at the concentrations indicated for 24 h. Equal volumes of concentrated 
medium were then immunoblotted with the anti-sAPPα 6E10 antibody. (A) Absolute levels and (B) levels 
standardised for cell viability. Results are means ± S.D. (n=3). Significant results are indicated: * = significant at 
p ≤ 0.05, ** = significant at p ≤ 0.01, *** = significant at p ≤ 0.005. 
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Figure 3.17. The effect of 24 h sodium acetate treatment on the production of sAPPβ by SH-SY5Y cells. Cells 
were treated with sodium acetate at the concentrations indicated for 24 h. Equal volumes of concentrated 
medium were then immunoblotted with the anti-sAPPβ antibody. (A) Absolute levels and (B) levels standardised 
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3.2.2. Acetic acid. 
 To further evaluate any potential role of pH in the DCA-mediated changes in APP 
expression/proteolysis, the effects of acetic acid on these processes were also examined (the 
structures of DCA and acetic acid are compared in Fig. 3.18.). Initially, SH-SY5Y cells were 
grown to confluence and treated for 24 h with UltraMEM containing molar concentrations of 
acetic acid equivalent to those previously employed with DCA. Cells and medium were 
subsequently harvested, processed and analysed, as described in the Materials and Methods 
section. Prior to concentrating, the pH of the conditioned medium was analysed. In contrast 
to the results obtained from medium treated with DCA (Fig. 3.10.) and sodium acetate (Fig. 
3.12.), the results (Fig. 3.19.) showed a significant decrease in the pH of medium containing 
acetic acid. Here the pH of the medium from control cultures was 7.03 ± 0.01, which 









Figure 3.18. The structures of sodium dichloroacetate (A) and acetic acid (B). 
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Figure 3.19. The effect of 24 h acetic acid treatment on the pH of conditioned medium. SH-SY5Y cells were 
treated with acetic acid at the concentrations indicated in UltraMEM for 24 h and the pH of the conditioned 
medium was measured. Results are means ± S.D. (n=3). Significant results are indicated: *** = significant at p ≤ 
0.05, ***** = significant at p ≤ 0.0005. 
 
 Given that acetic acid had the complete opposite effect on medium pH to that of DCA, 
the viability of SH-SY5Y cells treated with the former compound was also investigated using 
the MTS assay as described in the Materials and Methods section. The results (Fig. 3.20.) 
showed that acetic acid treatment led to a significant decrease in cell viability in both 10 and 
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Figure 3.20. The effect of 24 h acetic acid treatment on cell viability. SH-SY5Y cells were treated with acetic acid 
at the concentrations indicated in UltraMEM for 24 h. Cells were then quantified using an MTS assay in situ. 
Results are means ± S.D. (n=3). Significant results are indicated: ***** = significant at p ≤ 0.0005, ****** = 
significant at p ≤ 0.00005.  
 
Next, the effects of 24 h acetic acid treatment on the expression of APP and p53 and 
proteolysis of the former protein were examined. To this end, lysates prepared from drug-
treated cells were first immunoblotted with the anti-APP C-terminal antibody. The results (Fig. 
3.21.) revealed no significant differences in the expression of full-length APP following the 
treatment of cells with 10 mM acetic acid. However, cells treated with 20 mM acetic acid saw 
a significant increase in full-length APP expression (154.33 ± 17.83 % increase, relative to 
controls). Therefore, like DCA, acetic acid treatment leads to a significant increase in full-
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Figure 3.21. The effect of 24 h acetic acid treatment on the expression of full-length APP in SH-SY5Y cells. SH-
SY5Y cells were treated with acetic acid at the concentrations indicated for 24 h. Equal amounts of lysate protein 
were then immunoblotted with (A) anti-APP C-terminal and (B) anti-actin antibodies. Results are means ± S.D. 
(n=3). Significant results are indicated: *** = significant at p ≤ 0.005. 
 
 When 24 h acetic acid-treated cell lysates were immunoblotted with anti-p53 
antibody (Fig. 3.22.), significant decreases in the levels of this protein were observed in cells 
treated with both 10 and 20 mM acetic acid (26.32 ± 7.00 and 46.74 ± 15.40 % reductions, 
respectively, relative to controls). This was similar to the results obtained from sodium 
acetate treatments (which also reduced p53 levels), but the complete opposite to those 
obtained from DCA treated cells (which enhanced p53 levels). Therefore, it was clear that the 
DCA-induced alterations in p53 levels were not simply related to changes in extracellular pH.   
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Figure 3.22. The effect of 24 h acetic acid treatment on the levels of p53 in SH-SY5Y cells. SH-SY5Y cells were 
treated with acetic acid at the concentrations indicated for 24 h. Equal amounts of lysate protein were then 
immunoblotted with anti-p53 antibody. Results are means ± S.D. (n=3). Significant results are indicated: * = 
significant at p ≤ 0.05. 
 
 Next, conditioned medium from the 24 h acetic acid-treated cells was immunoblotted 
with anti-APP 6E10 antibody in order to detect sAPPα. Initially, the results were quantified in 
terms of the absolute amount of the protein fragment released by cells (Fig. 3.23A.). Here, no 
significant change was observed in either sAPP751/770α or sAPP695α. The results were also 
standardised to account for the decreases observed previously in cell viability (Fig. 3.20.). 
These latter results (Fig. 3.23B.) showed that there was a significant increase in sAPP695α 
production by cells treated with both 10 and 20 mM acetic acid (28.67 ± 4.15 and 138.17 ± 
11.61 % increases, respectively, relative to controls). These results also showed that cells 
treated with 20 mM saw a significant increase in sAPP751/770α production (179.86 ± 37.06 
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% increase, relative to controls). It is, therefore, worth noting that acetic acid treatments led 
to similar increases in sAPPα production to DCA treatments, despite having the opposite 
effect on extracellular pH. 
 The same conditioned medium samples were then immunoblotted for sAPPβ and the 
results (Fig. 3.24.) showed a significant increase in sAPPβ generation in acetic acid-treated 
cells. Non-standardised results (Fig. 3.24A.) revealed 41.15 ± 8.73 and 55.89 ± 14.90 % 
increases in sAPPβ production in cells treated with 10 and 20 mM acetic acid, respectively, 
relative to controls. When these results were corrected to account for changes in cell viability 
(Fig. 3.24B.), these differences were even more apparent. Therefore, as previously observed 
with sodium acetate treated cells, acetic acid treatment also increased sAPPβ production 
despite the opposing effects of the two compounds on pH. 
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Figure 3.23. The effect of 24 h acetic acid treatment on the production of sAPPα by SH-SY5Y cells. SH-SY5Y cells 
were treated with acetic acid at the concentrations indicated for 24 h. Equal volumes of concentrated medium 
were then immunoblotted with the anti-sAPPα 6E10 antibody. (A) Standard results and (B) viability corrected 
results. Results are means ± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05, *** = 
significant at p ≤ 0.005. 
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Figure 3.24. The effect of 24 h acetic acid treatment on the production of sAPPβ by SH-SY5Y cells. SH-SY5Y cells 
were treated with acetic acid at the concentrations indicated for 24 h. Equal volumes of concentrated medium 
were then immunoblotted with the anti-sAPPβ antibody. (A) Standard results and (B) corrected viability results. 
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3.3.  Summary. 
 The initial aim of this chapter was to reproduce previous data (Parkin et al., 
unpublished) showing that DCA, at concentrations of 10 and 20 mM, enhanced non-
amyloidogenic and impaired amyloidogenic processing of APP. The results in the current 
study also showed that 10 mM DCA was the minimum effective concentration of the drug in 
these respects. The same concentrations of DCA also enhanced p53 levels, although there 
was little effect on cell viability. Notably, when cells were treated with sodium acetate, similar 
changes in pH and cell viability were observed and the non-amyloidogenic production of 
sAPPα was also increased slightly. However, the effects of this compound on sAPPβ 
generation and p53 levels were the complete opposite of those observed with DCA (i.e. 
sodium acetate enhanced production of sAPPβ and decreased p53 levels whereas DCA 
impaired production of the former fragment and enhanced p53 levels). As such it is apparent 
that the effects of DCA on APP processing are not simply the consequence of an increase in 
the alkalinity of medium. When SH-SY5Y cells were treated with 10 and 20 mM concentrations 
of acetic acid, the pH of the conditioned medium, as one would expect for an acid, decreased 
in an exact opposite fashion to the effect mediated by DCA and sodium acetate. This drop in 
pH caused considerable decreases in cell viability although any cell death was probably not of 
an apoptotic manner as acetic acid also decreased p53 levels. Here, the increased acidity of 
the medium enhanced sAPPα generation (as seen with DCA and sodium acetate despite these 
compounds having an opposite effect to acetic acid on pH) and also enhanced sAPPβ 
generation.  
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 It is, therefore, apparent, given the different effects of DCA, sodium acetate and acetic 
acid on the proteolysis of APP, that the effect of the former drug in this respect cannot simply 
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4.  DCA-mediated changes in p53 levels and the regulation of APP 
 proteolysis. 
 In the preceding results section, it was demonstrated that DCA enhanced levels of p53 
expression in SH-SY5Y cell lysates (Fig. 3.3.). It has previously been shown that there is a 
reciprocal relationship between APP and p53 levels (Alves da Costa et al., 2006; Cuesta et al., 
2009). Therefore, in the current study, it was hypothesised that the changes in APP 
expression/proteolysis mediated by DCA might be related to cellular p53 levels. As such, the 
levels of the latter protein were experimentally manipulated and the effects of these changes 
on APP expression/proteolysis in DCA-treated cells were monitored. 
 
4.1.  Reactivating p53 and Inducing Tumour Apoptosis (RITA) enhancement 
of p53 levels. 
 Reactivating p53 and Inducing Tumour Apoptosis (RITA) is a drug in development for 
the treatment of cancer due to its ability to enhance cellular p53 levels (Merkel et al., 2017). 
The drug works by inducing a conformational change in the N-terminal region of p53, which 
impedes the bindings of regulators (such as MDM2) and results in p53 stabilisation and 
activation (Enge et al., 2009). Therefore, in the current study, RITA was used to enhance p53 
levels in SH-SY5Y cells and to examine the effects of this change on APP expression/proteolysis 
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4.1.1.  Optimisation of RITA concentrations. 
 Before assessing whether RITA could modify the effects of DCA on APP 
expression/proteolysis, it was necessary to determine which concentrations of the former 
drug enhanced p53 levels in SH-SY5Y cells and what effects these concentrations had on cell 
viability. Ideally, the subsequent experiments using DCA could then be performed using a RITA 
concentration that enhanced p53 expression without impacting too severely on cell viability. 
Initially, cells were grown to confluence and treated with a range of RITA concentrations 
between 0-25 µM (this range was adopted from Issaeva et al., 2004). After 24 h, cell viability 
was determined using the MTS assay as described in the Materials and Methods section. The 
results (Fig. 4.1.) showed that RITA concentrations at or below 5 µM had no significant effect 
on cell viability, whilst drug concentrations of 10 and 25 µM decreased viability by 22.50 ± 
7.05 and 27.50 ± 9.47 %, respectively, relative to controls. 
 
Figure 4.1. The effect of 24 h RITA treatment on SH-SY5Y cell viability. SH-SY5Y cells were treated with RITA at 
the concentrations indicated for 24 h. An MTS assay was then performed in situ. Results are means ± S.D. (n=3). 
Significant results are indicated: * = significant at p ≤ 0.05, ** = significant at p ≤ 0.01. 
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Lysates prepared from RITA-treated cells were then also subjected to immunoblotting 
using the anti-p53 antibody. The results (Fig. 4.2.) showed no significant changes in p53 levels 
at RITA concentrations lower than 5 µM. However, cells treated with 5, 10 and 25 µM RITA 
exhibited increases in levels of the protein of 64.97 ± 17.07, 79.71 ± 17.23, and 124.21 ± 37.60 
%, respectively, relative to controls. 
 
 
Figure 4.2. The effect of 24 h RITA treatment on the levels of p53 in SH-SY5Y cells. SH-SY5Y cells were treated 
with RITA at the concentrations indicated for 24 h. Cell lysates were then prepared, and equal amounts of protein 
were resolved and immunoblotted with (A) anti-p53 and (B) anti-actin antibodies. Results are means ± S.D. (n=3). 
Significant results are indicated: * = significant at p ≤ 0.05. 
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Figure 4.3. The effect of 24 h RITA treatment on the expression of full-length APP in SH-SY5Y cells. Cells were 
treated with RITA at the concentrations indicated for 24 h. Equal amounts of lysate protein were then 
immunoblotted with the anti-APP C-terminal antibody. Results are means ± S.D. (n=3). 
 
In order to assess the effect of this range of RITA concentrations on APP expression, 
the lysate samples were also immunoblotted with the anti-APP C-terminal antibody (Fig. 4.3.) 
but the results showed no significant effect of the drug on full-length APP expression. 
Conditioned medium from 24 h RITA-treated cells was then immunoblotted with anti-
APP 6E10 antibody to determine whether the drug had any effect on the non-amyloidogenic 
processing of APP. However, the results (Fig. 4.4.) revealed no changes in the levels of 
sAPP695α and sAPP751/770α generated by RITA-treated cells, regardless of whether or not 
levels of these fragments were corrected in order to account for RITA-induced changes in cell 
viability. 
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Figure 4.4. The effect of 24 h RITA treatment on the production of sAPPα. SH-SY5Y cells were treated with RITA 
at the concentrations indicated for 24 h. Equal volumes of concentrated medium were then immunoblotted 
with the anti-sAPPα 6E10 antibody. (A) Standard results and (B) viability corrected results. Results are means ± 
S.D. (n=3).   
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 When concentrated medium from 24 h RITA-treated cells was immunoblotted with 
the anti-sAPPβ antibody, the results (Fig. 4.5.) also showed no significant differences in sAPPβ 
production in cells treated with RITA at any concentration.  
 
Figure 4.5. The effect of 24 h RITA treatment on the production of sAPPβ. SH-SY5Y cells were treated with RITA 
at the concentrations indicated for 24 h. Equal volumes of concentrated medium were then immunoblotted 
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Interestingly, as RITA concentrations increased so too did the levels of a band detected 
by the anti-sAPPβ antibody at around 30 kDa (Fig. 4.6A.). Given that the fragment must have 
contained the C-terminal neoepitope generated on sAPPβ following β-secretase processing 
to be detected by this antibody, it was hypothesised that the fragment may result from an 
unknown protease cleavage of sAPPβ. Such a cleavage would also, in theory, lead to the 
generation of a correspondingly truncated N-terminal fragment generated from sAPPβ of 
around 70 kDa (full-length sAPPβ being about 100 kDa). As such, the same medium samples 
were also immunoblotted with antibody 22C11 which detects an epitope in the N-terminal 
region of APP. However, the results (Fig. 4.6B.) showed no accumulation of a band around 70 
kDa following RITA treatment. Interestingly though, a range of smaller (possibly N-terminal) 
fragments did accumulate in the range of 15-30 kDa suggesting possible degradation products 
of an N-terminal fragment. 
 
Figure 4.6. The effect of 24 h RITA treatment on the production of APP fragments by SH-SY5Y cells. SH-SY5Y 
cells were treated with RITA at the concentrations indicated for 24 h. Equal volumes of concentrated medium 
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4.1.2.  The effect of RITA on the DCA-mediated regulation of APP 
expression/proteolysis. 
 In the preceding section, it was determined that a RITA concentration of 5 µM 
substantially enhanced p53 levels in SH-SY5Y cells without leading to statistically significant 
decreases in cell viability. Therefore, despite the fact that RITA had no effect on APP 
expression or proteolysis when used alone, it was decided to examine whether this 
concentration of the drug might still be able to modify these events when used in combination 
with DCA. To this end, cells were grown to confluence and treated for 24 h with UltraMEM 
containing 10 mM DCA and/or 5 µM RITA before conducting an MTS cell viability assay as 
described in the Materials and Methods section. The results (Fig. 4.7.) showed that, as 
previously observed using this technique, DCA (10 mM) did not cause a decrease in viability 
nor did RITA when used on its own at 5 µM. However, when the two drugs were used in 
combination there was a 24.56 ± 6.64 % reduction in viability (relative to controls) which, 
interestingly, was significantly different not only from controls but also cultures treated with 








- 87 - 
 
 
Figure 4.7. The effect of RITA and/or DCA treatment on the viability of SH-SY5Y cells. SH-SY5Y cells were treated 
with DCA and/or RITA at the concentrations indicated for 24 h. Cell viability was then assessed using an MTS 
assay in situ. Results are means ± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05, ***** = 
significant at p ≤ 0.0005, ********* = significant at p ≤ 0.000005.  
 
 
The cell lysates were then immunoblotted with anti-p53 antibody and the results (Fig. 
4.8.) showed that when used singularly, as previously observed, both DCA and RITA caused 
significant increases in cellular p53 levels. Interestingly, when used in combination, the two 
drugs seemed to have an additive effect on p53 levels leading to a 172.29 ± 36.17 % increase 
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Figure 4.8. The effect of RITA and/or DCA treatment on p53 expression. SH-SY5Y cells were treated with DCA 
and/or RITA for 24 h. Cell lysates containing the same concentration of protein were then blotted with (A) anti-
p53 and (B) anti-actin antibody. Results are means ± S.D. (n=3). Significant results are indicated: * = significant 
at p ≤ 0.05, ** = significant at p ≤ 0.01.  
 
 Next, the effects of combined RITA and DCA treatments on APP expression and 
proteolysis were examined. The lysates from the previous experiment were also 
immunoblotted with the anti-APP C-terminal antibody but the results (Fig. 4.9.) showed no 
changes in APP expression. 
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Figure 4.9. The effect of RITA and/or DCA treatment on full-length APP expression. SH-SY5Y cells were treated 
with DCA and/or RITA for 24 h. Cell lysates containing the same concentration of protein were then blotted with 
the anti-APP C-terminal antibody. Results are means ± S.D. (n=3). 
 
 In order to see whether RITA might modify the effects of DCA on APP proteolysis, the 
conditioned medium from the same experiment was also immunoblotted with the anti-APP 
6E10 and anti-sAPPβ antibodies. However, the results (Fig. 4.10. and Fig. 4.11.) showed that 
whilst DCA, as previously observed, enhanced sAPPα and decreased sAPPβ production, RITA 
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Figure 4.10. The effect of RITA and/or DCA treatment on the generation of sAPPα by SH-SY5Y cells. Cells were 
treated for 24 h with RITA and/or DCA. Equal volumes of concentrated conditioned medium were then blotted 
with the anti-sAPPα 6E10 antibody. (A) Standard results. (B) Viability corrected results. Results are means ± S.D. 
(n=3). Significant results are indicated: * = significant at p ≤ 0.05.  
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Figure 4.11. The effect of RITA and/or DCA treatment on the generation of sAPP by SH-SY5Y cells. Cells were 
treated for 24 h with RITA and/or DCA. Equal volumes of concentrated conditioned medium were then blotted 
with the anti-sAPP antibody. (A) Standard results. (B) Viability corrected results. Results are means ± S.D. (n=3). 
Significant results are indicated: ** = significant at p ≤ 0.01, *** = significant at p ≤ 0.005, **** = significant at p 
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4.2.  siRNA knockdown of p53. 
 Next, the effects of depleting p53 using siRNA on the DCA-mediated regulation of APP 
expression/proteolysis were examined. 
 
4.2.1.  Transfection optimisation. 
Initially, suitable concentrations of transfection reagents and siRNA that gave 
sufficient p53 knockdown whilst not affecting cell viability were determined. SH-SY5Y cells 
were grown to 70 % confluence and the growth medium was then replaced with UltraMEM 
containing Dharmafect transfection reagent in the range 0-5 µl/ml (final culture medium 
concentrations) before culturing the cells for a further 24 h. An MTS assay was then 
performed to evaluate the effect of the transfection reagent on cell viability (see Materials 
and Methods). The results (Fig. 4.12.) showed that Dharmafect concentrations of 2.5 and 5 
µl/ml resulted in significant cytotoxicity (32.20 ± 3.77 and 40.50 ± 4.69 % decreases in viability, 
respectively, relative to controls). As such, the highest non-toxic concentration of 1 µl/ml was 
chosen for subsequent experiments. 
Next, the concentration of siRNA required to give suitable p53 knockdown without 
appreciable decreases in viability was ascertained. Here, the final 1 µl/ml Dharmafect 
concentration was employed in all samples but the final concentration of p53 siRNA was 
varied in the range 0-37.5 nM. As such, siRNA transfection was performed along with 
subsequent MTS analysis of cell viability and immunoblot analysis of p53 levels in cell lysates, 
according to the Materials and Methods section. The results (Fig. 4.13.) showed that none of 
the siRNA concentrations employed had a significant impact on cell viability.  
- 93 - 
 
 
Figure 4.12. The effect of Dharmafect transfection reagent on the viability of SH-SY5Y cells. Cells were grown 
to 70% confluence before treating with Dharmafect transfection reagent at the concentrations indicated in 
growth medium lacking antibiotic for 24 h. An MTS viability assay was then performed in situ. Results are means 




Figure 4.13. The effect of p53 siRNA transfection on the viability of SH-SY5Y cells. Cells were grown to 70 % 
confluence and transfected with the final siRNA concentrations indicated as described in the Materials and 
Methods section. An MTS assay was then performed in situ. Results are means ± S.D. (n=3). 
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 When p53 expression levels in cell lysates were analysed, the results (Fig. 4.14.) 
showed that the lowest siRNA concentration (2.5 nM) had no impact on p53 expression. 
However, 12.5, 25 and 37.5 nM concentrations reduced expression by 38.92 ± 14.05, 45.29 ± 
13.13 and 78.87 ± 3.64 %, respectively. Given that none of these siRNA concentrations caused 
significant toxicity, it was, therefore, decided that the highest (37.5 nM) concentration would 
be used for subsequent experiments. 
 
Figure 4.14. The effect of p53 siRNA concentrations on the expression of p53 in SH-SY5Y cells. Cells were grown 
to 70 % confluence and transfected with the final siRNA concentrations indicated as described in the Materials 
and Methods section. Equal amounts of cell lysate protein were then subjected to SDS-PAGE and 
immunoblotting using the anti-p53 antibody (see Materials and Methods). Results are means ± S.D. (n=3). 
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4.2.2. The effect of p53 siRNA knockdown on DCA-mediated changes in APP 
expression/proteolysis. 
 Next, the effect of siRNA depletion of p53 on the ability of DCA to regulate APP 
expression/proteolysis was examined. To this end, SH-SY5Y cells were grown to 70 % 
confluence before transfection, using a final Dharmafect concentration of 1 µl/ml and a final 
siRNA concentration of 37.5 nM. After a penultimate 48 h incubation in complete medium 
(containing antibiotics), the cells were further incubated for 24 h in UltraMEM in the absence 
or presence of 10 mM DCA. As might be expected from the previous experiments, none of 
these incubations resulted in significant decreases in cell viability (Fig. 4.15.).  
 
Figure 4.15. The effect of siRNA and DCA treatment on the viability of SH-SY5Y cells. Cells were grown to 70 % 
confluence and then transfected with either non-targeting (NT) or p53 siRNA as described in the Materials and 
Methods section. After a penultimate 48 h incubation in complete growth medium, the cells were incubated for 
a further 24 h in UltraMEM in the absence or presence of 10 mM DCA. An MTS assay was then performed in situ. 
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Cell lysates were then immunoblotted with the anti-p53 antibody and the results (Fig. 
4.16.) showed that, as previously observed, DCA enhanced endogenous p53 expression (in 
the presence of non-targeting (NT) siRNA in this instance) (46.81 ± 17.58 % increase, relative 
to controls). Treatment with p53 siRNA virtually completely ablated expression of this protein 
in cells that were not treated with DCA but, interestingly, this did not prevent the ability of 
DCA to promote p53 expression to the same level as in the NT siRNA cells treated with the 
drug. This may well suggest that the ability of DCA to promote p53 expression lies at a post-
translational level and perhaps in an ability to prevent degradation of the protein. Note that 
this experiment was repeated to further verify the result with p53 siRNA (see Appendix I). 
 
 
Figure 4.16. The effect of p53 knockout on DCA-mediated changes in p53 expression. SH-SY5Y cells were grown 
to 70 % confluence and then transfected with either non-targeting (NT) or p53 siRNA as described in the 
Materials and Methods section. After a penultimate 48 h incubation in complete growth medium, the cells were 
incubated for a further 24 h in UltraMEM in the absence or presence of 10 mM DCA. Equal amounts of cell lysate 
protein were then subjected to SDS-PAGE and immunoblotting using (A) anti-p53 and (B) anti-actin antibodies 
(see Materials and Methods). Results are means ± S.D. (n=3). Significant results are indicated: * = significant at 
p ≤ 0.05, **************** = significant at p ≤ 0.000000001. 
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Figure 4.17. The effect of siRNA treatment on DCA-mediated changes in full-length APP expression. SH-SY5Y 
cells were grown to 70 % confluence and then transfected with either non-targeting (NT) or p53 siRNA as 
described in the Materials and Methods section. After a penultimate 48 h incubation in complete growth 
medium, the cells were incubated for a further 24 h in UltraMEM in the absence or presence of 10 mM DCA. 
Equal amounts of cell lysate protein were then subjected to SDS-PAGE and immunoblotting using the anti-APP 
C-terminal antibody (see Materials and Methods). Results are means ± S.D. (n=3). 
 
 Next, the same cell lysates were immunoblotted with the anti-APP C-terminal 
antibody in order to determine how the combinations of siRNA and DCA treatments might 
impact on the expression of the protein. The results, however, showed no significant changes 
in APP expression (Fig. 4.17.). 
 The concentrated medium from the final 24 h DCA incubation was then 
immunoblotted with the anti-sAPPα 6E10 and anti-sAPPβ antibodies to characterise any 
changes in the production of these fragments. However, the results (Fig. 4.18. and Fig. 4.19.), 
whilst corroborating previous observations in this study showing that DCA enhanced non-
amyloidogenic whilst impairing amyloidogenic APP processing, did not reveal any impact of 
the siRNA treatments on the effects of DCA in these respects. 
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Figure 4.18. The effect of siRNA treatment on DCA-mediated changes in sAPPα production. SH-SY5Y cells 
were grown to 70 % confluence and then transfected with either non-targeting (NT) or p53 siRNA as described 
in the Materials and Methods section. After a penultimate 48 h incubation in complete growth medium, the 
cells were incubated for a further 24 h in UltraMEM in the absence or presence of 10 mM DCA. The 
conditioned medium from the final 24 h incubation was then concentrated, and equal volumes were subjected 
to SDS-PAGE and immunoblotting with anti-sAPPα 6E10 antibody as described in the Materials and Methods 
section. Results are means ± S.D. (n=3).  Significant results are indicated: * = significant at p ≤ 0.05, ** = 
significant at p ≤ 0.01, *** = significant at p ≤ 0.005, **** = significant at p ≤ 0.001. 
 
Figure 4.19. The effect of siRNA treatment on DCA-mediated changes in sAPP production. SH-SY5Y cells were 
grown to 70 % confluence and then transfected with either non-targeting (NT) or p53 siRNA as described in the 
Materials and Methods section. After a penultimate 48 h incubation in complete growth medium, the cells were 
incubated for a further 24 h in UltraMEM in the absence or presence of 10 mM DCA. The conditioned medium 
from the final 24 h incubation was then concentrated, and equal volumes were subjected to SDS-PAGE and 
immunoblotting with anti-sAPP antibody as described in the Materials and Methods section. Results are means 
± S.D.  (n=3). Significant results are indicated: *** = significant at p ≤ 0.005, ******* = significant at p ≤ 0.0001. 
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4.3.  Summary. 
 The aim of these experiments was to determine whether DCA-mediated changes in 
p53 levels might be responsible for the corresponding changes seen in APP 
expression/proteolysis. Treatment of cells with RITA resulted in a synergistic cytotoxic effect 
with DCA and an additive effect on the expression of p53. However, RITA did not alter the 
ability of DCA to alter APP metabolism. Interestingly, when siRNA was employed to deplete 
p53 expression, whilst working very effectively in the absence of DCA treatment, p53 siRNA 
did not result in a decreased expression of the protein in DCA-treated cells. This would suggest 
that the ability of DCA to enhance p53 expression works via a post-translational mechanism. 
Rather unsurprisingly, given the fact p53 expression in DCA-treated cells was not impacted on 
by prior p53 siRNA treatment, these siRNA treatments did not modify the effects of DCA on 




















Altered pyruvate and lactic acid metabolism as factors in the DCA-









- 101 - 
 
5.  Altered pyruvate and lactic acid metabolism as factors in the DCA-
 mediated regulation of APP proteolysis. 
 Previous studies have clearly demonstrated that DCA inhibits pyruvate dehydrogenase 
kinase, thereby impairing the phosphorylation and activation of PDH (Man et al., 2000; Li et 
al., 2009). The latter enzyme is responsible for the conversion of pyruvate to acetyl-CoA, 
thereby depleting the substrate for another enzyme, lactate dehydrogenase (LDH), which 
itself is responsible for the interconversion of pyruvate and lactate (Valvona et al., 2016). 
Therefore, in the current study, it was hypothesised that changes in the levels of lactate 
and/or pyruvate in DCA-treated SH-SY5Y cells might, in turn, regulate APP 
expression/proteolysis. As such, the metabolism of the protein was investigated in cells 
treated with these compounds or with LDH inhibitors. 
 
5.1. Lactate dehydrogenase inhibition. 
 As LDH-A is responsible for the conversion of pyruvate to lactate and LDH-B is largely 
responsible for the reciprocal reaction, inhibitors of both forms of the enzyme were 
investigated in terms of their ability to regulate APP expression/proteolysis. The first inhibitor 
used, GSK2837808A, inhibits both LDH-A and LDH-B with IC50 values of 1.9 and 14 nM, 
respectively (Massey, 2017). The second inhibitor used, FX11, has a Ki of 8 μM for LDH-A but 
does not affect LDH-B even at higher concentrations (Le et al., 2010). 
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5.1.1.  GSK2837808A (LDH-A and LDH-B inhibitor). 
Initially, the effect of this compound on the viability of SH-SY5Y cells was determined. 
Cells were grown to confluence and treated for 24 h with UltraMEM containing 0, 2, 5, 10, 15, 
or 25 nM concentrations of the inhibitor before analysing cell viability using the MTS assay, 
as described in the Materials and Methods section. The results (Fig. 5.1.) showed no 
significant effect on viability at any concentration. 
 
Figure 5.1. The effect of GSK2837808A (LDH-A and LDH-B inhibitor) on SH-SY5Y cell viability. Cells were grown 
to confluence and treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Cell viability was 
then determined using the MTS assay, as described in the Materials and Methods section. Results are means ± 
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 Given that DCA also altered p53 levels (see preceding results chapters), the effect of 
GSK2837808A on the level of this protein was also monitored in the current experiments. As 
such, lysates were prepared from inhibitor-treated cells and subjected to immunoblot 
analysis using the anti-p53 antibody. However, the results (Fig. 5.2.) showed no effect of 
GSK2837808A on the levels of this protein. 
 Next, the effects of GSK2837808A on APP expression and proteolysis were 
investigated. The lysates from the previous experiment were initially immunoblotted with the 
anti-APP C-terminal antibody and the results, as with p53, showed no significant change in 
APP expression (Fig. 5.3.). 
 
 
Figure 5.2. The effect of GSK2837808A (LDH-A and LDH-B inhibitor) on p53 levels. SH-SY5Y cells were grown to 
confluence and treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Cell lysates were 
prepared, and equal amounts of protein were subjected to SDS-PAGE and immunoblotting using the (A) anti-
p53 and (B) anti-actin antibodies, as described in the Materials and Methods section. Results are means ± S.D. 
(n=6). 
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Figure 5.3. The effect of GSK2837808A (LDH-A and LDH-B inhibitor) on APP expression. SH-SY5Y cells were 
grown to confluence and treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Cell lysates 
were prepared, and equal amounts of protein were subjected to SDS-PAGE and immunoblotting using the anti-
APP C-terminal antibody, as described in the Materials and Methods section. Results are means ± S.D. (n=6). 
 
 The effects of GSK2837808A on the generation of sAPPα and sAPPβ were also 
monitored by immunoblotting equal volumes of concentrated conditioned medium with 
antibodies against these protein fragments. Results using the anti-APP 6E10 antibody (Fig. 
5.4.) revealed a significant decrease in both sAPP695α and sAPP751/770α production by cells 
treated with 25 nM GSK2837808A (19.42 ± 6.05 and 30.22 ± 7.55 % decreases relative to 
controls, respectively). However, no significant differences were observed in the production 
of either fragment in cells treated with all other concentrations of GSK2836808A.  
 Next, the same medium samples were immunoblotted with the anti-sAPPβ antibody. 
The results (Fig. 5.5.) showed a significant increase in sAPPβ production in cells treated with 
GSK2837808A at concentrations of 10, 15 and 25 nM (335.46 ± 68.77, 416.80 ± 92.83 and 
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400.53 ± 109.67 % increases, respectively). However, cells treated with 2 and 5 nM 
GSK2837808A saw no significant difference in sAPPβ production. 
 In summary, GSK2837808A appears to reduce sAPPα (at the highest concentration) 
and enhance sAPPβ production, the exact opposite of previous observations in DCA-treated 
cells. What this data does show, however, is that the inhibition of LDH does have the potential 
to alter both amyloidogenic and non-amyloidogenic APP processing, as was the case for DCA. 
 
Figure 5.4. The effect of GSK2837808A (LDH-A and LDH-B inhibitor) on the production of sAPPα by SH-SY5Y 
cells. Cells were grown to confluence and then treated with the indicated inhibitor concentrations in UltraMEM 
for 24 h. Conditioned medium was then processed and subjected to SDS-PAGE and immunoblotting using the 
anti-sAPPα 6E10 antibody, as described in the Materials and Methods section. Results are means ± S.D. (n=6). 
Significant results are indicated: ***** = significant at p ≤ 0.0005. 
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Figure 5.5. The effect of GSK2837808A (LDH-A and LDH-B inhibitor) on the production of sAPPβ by SH-SY5Y 
cells. Cells were grown to confluence and then treated with the indicated inhibitor concentrations in UltraMEM 
for 24 h. Conditioned medium was then processed and subjected to SDS-PAGE and immunoblotting using the 
anti-sAPPβ antibody, as described in the Materials and Methods section. Results are means ± S.D. (n=6). 
Significant results are indicated: ***** = significant at p ≤ 0.0005, ****** = significant at p ≤ 0.0001. 
 
5.1.2.  FX11 (LDH-A inhibitor). 
 The experiments in the preceding sections were repeated using FX11, which is a 
specific LDH-A inhibitor (Ki of 8 μM). Again, cells were grown to confluence and treated for 
24 h with inhibitor before analysing cell viability using the MTS assay (Fig. 5.6.). Unlike 
GSK2837808A, cultures treated with FX11 exhibited significantly decreased viability at 
inhibitor concentrations of 10, 50 and 100 μM (27.08 ± 15.27, 54.01 ± 11.50, 93.92 ± 7.45 % 
decreases, respectively, relative to controls). 
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Figure 5.6. The effect of FX11 (LDH-A specific inhibitor) on SH-SY5Y cell viability. Cells were grown to confluence 
and then treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Cell viability was then 
determined using the MTS assay as described in the Materials and Methods section. Results are means ± S.D. 
(n=3). Significant results are indicated: * = significant at p ≤ 0.05, *** = significant at p ≤ 0.005, ***** = significant 
at p ≤ 0.0005. 
 
 Next, the effects of FX11 on p53 levels in cell lysates was analysed. Note that only 
inhibitor concentrations of 1 and 10 μM were investigated in this respect due to the dramatic 
decreases in cell viability observed previously at higher inhibitor concentrations. The results 
(Fig. 5.7.) revealed a significant increase in p53 levels in cells treated with 10 µM FX11 (172.40 
± 40.80 % increase, relative to controls), perhaps reflective of significant cell death occurring 







- 108 - 
 
 
Figure 5.7. The effect of FX11 (LDH-A inhibitor) on p53 levels. SH-SY5Y cells were grown to confluence and then 
treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Cell lysates were prepared, and equal 
amounts of protein were subjected to SDS-PAGE and immunoblotting using the (A) anti-p53 and (B) anti-actin 
antibodies as described in the Materials and Methods section. Results are means ± S.D. (n=3). Significant results 
are indicated: ** = significant at p ≤ 0.01. 
 
 Lysates from the same experiments were also immunoblotted with the anti-APP C-
terminal antibody and the results (Fig. 5.8.) showed no effect of 1 and 10 μM FX11 on full-
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Figure 5.8. The effect of FX11 (LDH-A inhibitor) on APP expression. SH-SY5Y cells were grown to confluence and 
then treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Cell lysates were prepared, and 
equal amounts of protein were subjected to SDS-PAGE and immunoblotting using the anti-APP C-terminal 
antibody as described in the Materials and Methods section. Results are means ± S.D. (n=3). 
 
The effects of the inhibitor on APP proteolysis were also investigated by 
immunoblotting concentrated conditioned medium from these experiments with anti-APP 
6E10 and anti-sAPPβ antibodies. Again, it is worth noting that only the results using the lower 
1 and 10 μM FX11 concentrations are shown due to high levels of toxicity at the higher 
inhibitor concentrations. The results (Fig. 5.9A.) showed that cells treated with 1 µM FX11 
generated significantly more sAPP751/770α (28.03 ± 11.00 % increase, relative to controls) 
and this difference even remained significant when the results were adjusted to account for 
changes in cell viability (Fig. 5.9B.). Contrastingly, cells treated with 10 µM FX11 exhibited 
decreases in both sAPP695α and sAPP751/770α production (Fig. 5.9A.) (24.34 ± 7.18, and 
65.76 ± 12.27 % decreases, respectively). However, only the difference in sAPP751/770α 
remained significant at this concentration once the results were adjusted for cell viability (Fig. 
5.9B.). The corresponding results for sAPPβ showed no significant changes in the production 
of this fragment when the cells were treated with either 1 or 10 μM FX11 (Fig. 5.10.). 




Figure 5.9. The effect of FX11 (LDH-A inhibitor) on the production of sAPPα by SH-SY5Y cells. Cells were grown 
to confluence and then treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Equal volumes 
of concentrated medium were then immunoblotted with anti-sAPPα 6E10 antibody. Results are means ± S.D. 
(n=3). (A) Standard results and (B) viability corrected results. Significant results are indicated: * = significant at 
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Figure 5.10. The effect of FX11 (LDH-A inhibitor) on the production of sAPPβ by SH-SY5Y cells. Cells were grown 
to confluence and then treated with the indicated inhibitor concentrations in UltraMEM for 24 h. Equal volumes 
of concentrated medium were then immunoblotted with anti-sAPPβ antibody. Results are means ± S.D. (n=3). 
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5.2.  Pyruvate and lactic acid supplementation. 
Previous studies have shown that DCA activates PDH, leading to a greater conversion 
of pyruvate to acetyl-coA and a possible decrease in the cellular pool of the former compound 
(Mann et al., 2000; Li et al., 2009). The lack of pyruvate has also been shown to result in the 
depletion of cellular lactic acid levels (Stacpoole et al., 2003). Furthermore, Xiang et al. (2010) 
showed that lactic acid treatment decreased non-amyloidogenic APP processing in SH-SY5Y 
cells. Consequently, in the current study, it was hypothesised that changes in the levels of 
these metabolites might be responsible for the observed effects of DCA on APP 
expression/proteolysis. As such, SH-SY5Y cells were supplemented with these compounds 
and APP metabolism was subsequently monitored. 
 
5.2.1.  Pyruvate. 
Cells were grown to confluence and treated for 24 h with UltraMEM containing 
pyruvate in the concentration range 1-100 mM. Note that the basal pyruvate concentration 
in UltraMEM is 1 mM; as such this concentration was used as the control in this set of 
experiments. Following the pyruvate treatment, cell viability was monitored using the MTS 
assay as described in the Materials and Methods section. The results (Fig. 5.11.) showed that 
there was a significant increase in viability when the cells were treated with 10 mM pyruvate 
(23.27 ± 7.11 % increase, relative to controls). However, cells treated with 50 and 100 mM 
pyruvate exhibited decreased viability (35.08 ± 3.61 and 68.59 ± 7.72 % decreases, 
respectively, relative to controls). 
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Figure 5.11. The effect of pyruvate on SH-SY5Y cell viability. Cells were grown to confluence and then treated 
with the indicated pyruvate concentrations in UltraMEM for 24 h. Cell viability was then determined using the 
MTS assay as described in the Materials and Methods section. Results are means ± S.D. (n=3). Significant results 
are indicated: ** = significant at p ≤ 0.01, ***** = significant at p ≤ 0.0005. 
 
 Next, the effect of pyruvate concentration on the p53 levels in cell lysates was 
evaluated by immunoblotting. The results (Fig. 5.12.) demonstrated unaltered levels of the 
protein at the lower pyruvate concentrations but levels did increase significantly at 50 and 
100 mM concentrations (100.64 ± 37.86 and 93.44 ± 21.10 % increases, respectively, relative 
to controls). Note that this latter observation might well have been linked to the large 
decreases in cell viability observed at higher pyruvate concentrations (Fig. 5.11.).  
 The expression of APP was also quantified in lysates from cells treated with pyruvate. 
However, the results (Fig. 5.13.) showed no significant changes in the expression of this 
protein following pyruvate treatment.  
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Figure 5.12. The effect of pyruvate on p53 levels. SH-SY5Y cells were grown to confluence and then treated with 
the indicated pyruvate concentrations in UltraMEM for 24 h. Cell lysates were prepared, and equal amounts of 
protein were subjected to SDS-PAGE and immunoblotting using the (A) anti-p53 and (B) anti-actin antibodies as 
described in the Materials and Methods section. Results are means ± S.D. (n=3). Significant results are indicated: 
* = significant at p ≤ 0.05. 
 
Figure 5.13. The effect of pyruvate on APP expression. SH-SY5Y cells were grown to confluence and then treated 
with the indicated pyruvate concentrations in UltraMEM for 24 h. Cell lysates were prepared, and equal amounts 
of protein were subjected to SDS-PAGE and immunoblotting using the anti-APP C-terminal antibody as described 
in the Materials and Methods section. Results are means ± S.D. (n=3).  
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 Next, the effects of pyruvate concentration on the levels of sAPPα and sAPPβ 
generated by SH-SY5Y cells were investigated. Note that, given the high levels of toxicity at 
50 and 100 mM pyruvate, these latter results are only shown for 1, 5 and 10 mM pyruvate-
treated cells. Concentrated conditioned medium was initially immunoblotted with anti-APP 
6E10 antibody and the results (Fig. 5.14A.) showed that sAPPα levels remained unchanged at 
pyruvate treatment concentrations of 5 mM (relative to 1mM controls). However, there was 
a significant decrease in the production of sAPP751/770α (but not sAPP695α) when cells were 
treated with 10 mM pyruvate and values were adjusted in order to take into account cell 
viability (55.17 ± 20.85 % reduction, relative to controls) (Fig. 5.14B.). Interestingly, when the 
same medium samples were immunoblotted in order to detect sAPPβ, a corresponding 
increase in sAPPβ levels was observed (Fig. 5.15A.) although significance was lost when the 
samples were adjusted for cell viability (Fig. 5.15B). 
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Figure 5.14. The effect of pyruvate on the production of sAPPα by SH-SY5Y cells. Cells were grown to 
confluence and then treated with the indicated pyruvate concentrations in UltraMEM for 24 h. Equal volumes 
of concentrated medium were then immunoblotted with anti-sAPPα 6E10 antibody. Results are means ± S.D. 
(n=3). (A) Standard results and (B) viability corrected results. Significant results are indicated: * = significant at 













Figure 5.15. The effect of pyruvate on the production of sAPPβby SH-SY5Y cells. Cells were grown to 
confluence and then treated with the indicated pyruvate concentrations in UltraMEM for 24 h. Equal volumes 
of concentrated medium were then immunoblotted with anti-sAPPβ antibody. Results are means ± S.D. (n=3). 
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5.2.2.  Lactic acid. 
 Here, the ability of lactic acid (either singularly or in combination with DCA) to alter 
APP expression/proteolysis was investigated. Lactic acid concentrations of 6 and 12 mM were 
chosen based on a previous study by Xiang et al. (2010) where the authors demonstrated an 
increase in non-amyloidogenic APP processing at these concentrations. In the current study, 
SH-SY5Y cells were grown to confluence and treated for 24 h with either DCA (10 mM) or 
lactic acid (6 mM or 12 mM) or combinations of the two compounds. Cell viability was then 
analysed using the MTS assay as described in the Materials and Methods section. The results 
(Fig. 5.16.) demonstrated that, as previously observed, DCA alone (10 mM) did not result in 
any decrease in cell viability. However, when the drug was used in combination with 6 mM 
lactic acid there was a 9.57 ± 3.39 % decrease in cell viability relative to controls. Similarly, 
there were also small but significant decreases in viability when the cells were treated with 
either 12 mM lactic acid alone or in combination with DCA (11.92 ± 0.79 and 13.93 ± 1.19 % 
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Figure 5.16. The effect of DCA and lactic acid on SH-SY5Y cell viability. Cells were grown to confluence and 
then treated with the indicated DCA and lactic acid concentrations in UltraMEM for 24 h. Cell viability was then 
determined using the MTS assay as described in the Materials and Methods section. Results are means ± S.D. 
(n=3). Significant results are indicated: * = significant at p ≤ 0.05, *** = significant at p ≤ 0.005. 
 
 Next, the effect of lactic acid/DCA treatments on p53 in cell lysates was examined by 
immunoblotting (Fig. 5.17.). As previously observed, DCA caused an increase in p53 levels 
when used on its own (123.65 ± 20.87 % increase relative to controls). Perhaps more 
interestingly, lactic acid, when used on its own at 6 and 12 mM, also enhanced p53 levels 
(143.82 ± 42.38 and 109.53 ± 14.84 % increases, respectively, relative to controls). Notably 
these increases were not additive in the presence of DCA where lactic acid (at 6 and 12 mM) 
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Figure 5.17. The effect of DCA and lactic acid on p53 levels. SH-SY5Y cells were grown to confluence and then 
treated with the indicated DCA and lactic acid concentrations in UltraMEM for 24 h. Cell lysates were prepared, 
and equal amounts of protein were subjected to SDS-PAGE and immunoblotting using the (A) anti-p53 and (B) 
anti-actin antibodies as described in the Materials and Methods section. Results are means ± S.D. (n=3). 
Significant results are indicated: * = significant at p ≤ 0.05, ** = significant at p ≤ 0.01. 
 
 The same lysate samples from DCA/lactic acid-treated cells were then also 
immunoblotted with the anti-APP C-terminal antibody in order to examine full-length APP 
expression. The results (Fig. 5.18.) showed that neither compound either alone or in 
combination had any significant effect on APP expression at the concentrations employed. 
 Next, the effects of DCA/lactic acid on the proteolysis of APP were investigated by 
immunoblotting concentrated conditioned medium samples from the preceding experiments 
with anti-APP 6E10 and anti-sAPPβ antibodies. 
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Figure 5.18. The effect of DCA and lactic acid on APP expression. SH-SY5Y cells were grown to confluence and 
then treated with the indicated DCA and lactic acid concentrations in UltraMEM for 24 h. Cell lysates were 
prepared, and equal amounts of protein were subjected to SDS-PAGE and immunoblotting using the anti-APP C-
terminal antibody as described in the Materials and Methods section. Results are means ± S.D. (n=3).  
 
 The results using the former antibody (Fig. 5.19.) showed that, whilst DCA (as 
previously observed) enhanced sAPPα production, lactic acid had no effect in this respect 
when used alone at either 6 or 12 mM concentrations. Furthermore, the combination of DCA 
and lactic acid had no additive effects over and above the effect of the former drug alone in 
relation to sAPPα production. Results using the anti-sAPPβ antibody (Fig. 5.20.) showed that, 
as previously observed, DCA decreased sAPPβ production. Interestingly, when used at the 
lower 6 mM (and not 12 mM) concentration, lactic acid alone enhanced sAPPβ production 
(Fig. 5.20A.; 51.35 ± 28.45 % increase), a difference that remained when the values were 
adjusted to consider the minor alterations observed in cell viability (Fig. 5.20B.). Notably, 
when the cells were co-treated with DCA and lactic acid, the latter compound did not 
significantly modify the ability of DCA to reduce sAPPβ production. 
 




Figure 5.19. The effect of DCA and lactic acid on the production of sAPPα by SH-SY5Y cells. Cells were grown 
to confluence and then treated with the indicated DCA and lactic acid concentrations in UltraMEM for 24 h. 
Equal volumes of concentrated medium were then immunoblotted with anti-sAPPα 6E10 antibody. (A) Standard 
results and (B) viability corrected results. Results are means ± S.D. (n=3). Significant results are indicated: * = 
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Figure 5.20. The effect of DCA and lactic acid on the production of sAPPβ by SH-SY5Y cells. Cells were grown 
to confluence and then treated with the indicated DCA and lactic acid concentrations in UltraMEM for 24 h. 
Equal volumes of concentrated medium were then immunoblotted with anti-sAPPβ antibody. (A) Standard 
results and (B) viability corrected results. Results are means ± S.D. (n=3). Significant results are indicated: * = 
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 As mentioned previously, Xiang et al. (2010) reported a significant increase in sAPPα 
generation in SH-SY5Y cells following lactic acid treatment. In the current study, we chose 
initially to incubate SH-SY5Y cells with lactic acid for 24 h as this tied in with previous 
experiments using 24 h DCA treatments. However, it was subsequently noted that Xiang et 
al. conducted their treatments over just a 6 h treatment and, as such, it was hypothesised 
that the observed lack of effect on sAPPα generation (Fig. 5.19.) in the previous study might 
have been due to the differences in time scales employed. Therefore, the DCA/lactic acid 
treatment experiments were repeated but using a shorter 6 h incubation period.  
 Viability results (Fig. 5.21.) indicated that there was a very slight but significant 
decrease in viability observed in cells treated with 6 mM and 12 mM lactic acid for 6 h, both 
alone and in combination with DCA. 
 
Figure 5.21. The effect of 6h DCA and lactic acid treatment on SH-SY5Y cell viability. Cells were grown to 
confluence and then treated with the indicated DCA and lactic acid concentrations in UltraMEM for 6 h. Cell 
viability was then determined using the MTS assay as described in the Materials and Methods section. Results 
are means ± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05. 
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 Next, cell lysates from 6 h DCA/lactic acid-treated cells were immunoblotted in order 
to monitor p53 levels. The results (Fig. 5.22.) showed that DCA, when used alone, enhanced 
p53 levels even after this much shorter treatment duration (168.84 ± 6.63 % increase relative 
to controls). As observed with the longer (24 h) treatments, lactic acid alone also enhanced 
p53 levels at 6 h (83.64 ± 23.85 and 60.24 ± 26.97 % increases relative to controls for 6 and 
12 mM lactic acid, respectively). Although, notably this effect was not significant at the higher 
lactic acid concentration. Combining lactic acid with DCA did not modify the ability of the 
latter compound to alter p53 levels. 
 
Figure 5.22. The effect of shorter (6 h) DCA and lactic acid treatments on p53 levels. SH-SY5Y cells were grown 
to confluence and then treated with the indicated DCA and lactic acid concentrations in UltraMEM for 6 h. Cell 
lysates were prepared, and equal amounts of protein were subjected to SDS-PAGE and immunoblotting using 
(A) anti-p53 and (B) anti-actin antibodies as described in the Materials and Methods section. Results are means 
± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05, ** = significant at p ≤ 0.01, **** = 
significant at p ≤ 0.001. 
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The same lysate samples were then immunoblotted with the anti-APP C-terminal 
antibody to monitor APP expression. The results (Fig. 5.23.) showed a significant increase in 
full-length APP expression in cells treated with 10 mM DCA following this 6 h treatment (91.84 
± 20.57 % relative to controls) perhaps suggesting that such an increase might be transient 
given the fact that previous experiments had shown no change in APP expression in 10 mM 
DCA-treated cells at 24 h. Similarly, whereas earlier experiments (Fig. 5.18.) had shown no 
change in APP expression after 24 h lactic acid treatment, in this later 6 h experiment, 
expression was increased by 72.84 ± 15.50 and 72.67 ± 9.86%, respectively, at 6 and 12 mM 
lactic acid. However, again, the combination of both DCA and lactic acid did not alter the 
ability of each compound individually to alter APP expression. 
 
Figure 5.23. The effect of shorter (6 h) DCA and lactic acid treatments on APP expression. SH-SY5Y cells were 
grown to confluence and then treated with the indicated DCA and lactic acid concentrations in UltraMEM for 6 
h. Cell lysates were prepared, and equal amounts of protein were subjected to SDS-PAGE and immunoblotting 
using the anti-APP C-terminal antibody as described in the Materials and Methods section. Results are means ± 
S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05, ** = significant at p ≤ 0.01. 
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 Next, the conditioned medium from the 6 h DCA/lactic acid treatments was 
immunoblotted in order to quantify the effects of this shorter incubation time on sAPPα and 
sAPPβ generation. In terms of sAPPα production, the results (Fig. 5.24.) again showed an 
increase in the generation of this fragment following DCA treatment. However, lactic acid did 
not modify the effect of DCA and additionally failed to enhance the generation of this product 
once the results were altered to account for viability. In relation to sAPPβ, the results (Fig. 
5.25.) showed that, as with previous 24 h incubations, DCA reduced the generation of this 
fragment after only 6 h. However, again, lactic acid failed to have any effect on this aspect of 
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Figure 5.24. The effect of shorter (6 h) DCA and lactic acid treatments on the production of sAPPα by SH-SY5Y 
cells. Cells were grown to confluence and then treated with the indicated DCA and lactic acid concentrations in 
UltraMEM for 24 h. Equal volumes of concentrated medium were then immunoblotted with anti-sAPPα 6E10 
antibody. (A) Standard results and (B) viability corrected results. Results are means ± S.D. (n=3). Significant 
results are indicated: * = significant at p ≤ 0.05, ** = significant at p ≤ 0.01, *** = significant at p ≤ 0.005, **** = 
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Figure 5.25. The effect of shorter (6 h) DCA and lactic acid treatments on the production of sAPPβ by SH-SY5Y 
cells. Cells were grown to confluence and then treated with the indicated DCA and lactic acid concentrations in 
UltraMEM for 24 h. Equal volumes of concentrated medium were then immunoblotted with anti-sAPPβ 
antibody. (A) Standard results and (B) viability corrected results. Results are means ± S.D. (n=3). Significant 









- 130 - 
 
5.3.  Summary. 
 The overarching aim of this chapter was to investigate whether DCA was able to 
regulate APP expression/proteolysis through alterations in cellular pyruvate and/or lactic acid 
concentrations.  
 Initially, two inhibitors of LDH were employed, GSK2837808A (an inhibitor of both 
LDH-A and LDH-B) and FX11 (a specific inhibitor of LDH-A). The former compound saw no 
significant effect on viability at any concentration, whilst the latter was toxic at all but the 
lowest concentration employed. This toxicity was reflected in terms of p53 levels in that 
GSK2837808A did not alter expression and FX11 enhanced expression at the point at which 
the compound became toxic to cells. Neither compound affected full-length APP expression, 
whilst FX11 saw an increase in sAPPα production at sub-toxic inhibitor concentrations and 
GSK2837808A saw a decrease in sAPPα production at the highest concentration. Interestingly, 
GSK2837808A enhanced sAPPβ production at concentrations over 10 nM, whereas FX11 had 
no significant effect in this respect at non-toxic concentrations of the inhibitor. Clearly, there 
is a complex relationship between these two LDH inhibitors and APP proteolysis; this 
relationship is discussed further in the Discussion section of this report. 
 Pyruvate supplementation of SH-SY5Y cells had a biphasic effect on cell viability, 
increasing viability at 10 mM whilst becoming toxic at higher concentrations. The toxic effect 
of pyruvate above 10 mM was reflected in the increased p53 levels observed in cells treated 
with 50 and 100 mM concentrations of this metabolite. Pyruvate did not modify APP 
expression but did slightly decrease sAPPα generation at 10 mM whilst having no significant 
effect on sAPPβgeneration (after adjusting for viability changes). 
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 Perhaps the most interesting results in the current chapter came from the lactic acid 
supplementation experiments. Here, following 24 h incubations, the metabolite effected a 
very small but significant decrease in the viability of cell cultures. Interestingly, despite only 
these small viability changes, lactic acid dramatically enhanced p53 levels (to a similar extent 
as DCA). However, the effects of DCA and lactic acid on p53 levels were not additive. Neither 
DCA nor lactic acid altered APP expression following a 24 h incubation. As previously 
observed, 24 h DCA treatments enhanced non-amyloidogenic and inhibited amyloidogenic 
APP processing. However, lactic acid did not regulate these proteolytic events when used 
singularly nor did it modify the ability of DCA to regulate these events.  
 It is notable that the changes in p53 levels mediated by lactic acid were a relatively 
rapid event as the expression of this protein also increased following a much shorter 6 h 
incubation of cells with the metabolite. Similarly, it is also notable that both lactic acid and 
DCA (alone or in combination, although the effect was not additive) enhanced APP expression 
over 6 h whereas neither compound altered the expression of this protein over the longer 24 
h time course. This might suggest an initial burst in APP expression following 6 h lactic acid 
and/or DCA treatment with a subsequent return to control values by 24 h. Even at this shorter 
time point, however, lactic acid alone did not alter APP proteolysis, nor did it impact on the 
ability of DCA to regulate proteolysis (although DCA still enhanced non-amyloidogenic and 
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6.  The effects of DCA on BACE1 activity and APP subcellular localisation. 
 Previous studies have demonstrated that the inhibition of BACE1 leads to enhanced 
non-amyloidogenic processing and reduced amyloidogenic processing of APP (Cai et al., 2001; 
Ohno et al., 2004; McConlogue et al., 2007; Yan et al., 2014). Additionally, changes in the 
subcellular localisation of APP are known to affect proteolytic processing of the protein due 
to altered exposure of the substrate to BACE1 (Perez et al., 1999; Carey et al., 2005; Sano et 
al., 2006; Choy et al., 2012).  
 In the current study, it was, therefore, hypothesised that DCA might act either by 
reducing BACE1 activity (note that previous studies in our laboratory have shown that 
ADAM10 activity was unaffected by DCA; Parkin et al., unpublished data) and/or by altering 
the subcellular distribution of the APP substrate. 
 
6.1.   The effect of DCA on BACE1 activity.  
 In order to determine whether DCA altered BACE1 activity in SH-SY5Y cells, a 
fluorescence-based assay was employed (see Materials and Methods). Cells were grown to 
confluence and treated for 24 h with 0, 10 or 20 mM DCA in UltraMEM. Cell lysates were 
prepared according to the manufacturer’s instructions and assayed for BACE1 activity. 
Following the assay, protein concentrations in the lysates were determined and the results 
adjusted in order to account for minor differences in protein concentrations between the 
lysate samples. The results (Fig. 6.1.) were conclusive in that they clearly showed that DCA 
did not alter total cellular BACE1 activity. 
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Figure 6.1. The effect of DCA treatment on BACE1 activity in SH-SY5Y cells. Confluent SH-SY5Y cells were treated 
with DCA at the concentrations indicated for 24 h. Lysates were then prepared and assayed using a BACE1 
activity assay kit according to the manufacturer’s instructions. Results were adjusted to account for differing 
protein levels and are means ± S.D. (n=3).  
 
6.2. The effect of DCA on APP subcellular localisation. 
 It was hypothesised that DCA may alter the subcellular localisation of APP resulting in 
differing exposure to the enzymes of the non-amyloidogenic and amyloidogenic processing 
pathways. In order to test this hypothesis, immunofluorescence microscopy was used to 
analyse APP subcellular distribution in the absence or presence of 10 mM DCA. 
 Initially, the working dilution of the anti-APP antibody WO2 stock was optimised and 
the manufacturer recommended concentrations of antibodies against organelle marker 
proteins for lysosomes (LAMP1), cis-Golgi (GM130) and late endosomes (Rab6A) were tested. 
Cells were grown to 60 % confluence (a lower level of confluence was employed to visualise 
individual cells) and processed for immunofluorescence as described in the Materials and 
Methods section (note that the cells were not treated with DCA in this first experiment). The 
results (Fig. 6.2A-E) showed that, whilst a strong perinuclear staining was achieved at the 
supplier recommendation of 1 in 20 dilution of the anti-APP WO2 antibody (Fig. 6.2A.), equally 
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(if not better) clarity could be achieved at a 1 in 50 dilution (Fig. 6.2B.). As such, this latter 
dilution was adopted for subsequent experiments primarily for economic reasons. As far as 
the organelle marker antibodies were concerned, the recommended concentrations of 
LAMP1 (Fig. 6.2F.) and Rab6A (Fig. 6.2H), clearly stained defined structures likely 
corresponding to lysosomes and late endosomes, respectively. However, the anti-GM130 
antibody, at the recommend concentration (Fig. 6.2G.) gave somewhat inconsistent staining 
between cells; as such, a higher concentration of 40 μg/ml was adopted for subsequent 
experiments. 
 To gain an idea as to whether the anti-APP WO2 antibody was detecting APP and not 
cross-reacting with another protein, the hydroxamic acid inhibitor batimastat was employed. 
Here, the hypothesis was that this compound would inhibit shedding of APP by ADAM10 at 
the cell surface thereby leading to changes in the subcellular distribution of the former 
protein. If the WO2 antibody was picking up another protein (other than ADAM substrates) 
then batimastat would not lead to any changes in the subcellular fluorescence following 
immunodetection with the WO2 antibody. To this end, cells were again grown to 60 % 
confluence and then treated for 24 h in the absence or presence of batimastat (5 μM) before 
processing for immunofluorescence microscopy (see Materials and Methods). The control 
images (i.e. no batimastat) (Fig. 6.3.) revealed that APP showed little co-localisation with the 
lysosomal marker, LAMP1 and the strongest co-localisation with the cis-Golgi marker, GM130. 
There was also an intermediate level of co-localisation with the late endosomal marker, 
Rab6A. However, when the SH-SY5Y cells were pre-treated for 24 h with batimastat (Fig. 6.4.) 
there was a much greater co-localisation of APP with the lysosomal marker, LAMP1, a visible 
decrease in cis-Golgi localisation and a more defined localisation in the endosomes. 











































































































































































































































































































































Figure 6.3. The localisation of APP in control SH-SY5Y cells. Human SH-SY5Y cells were initially grown to 60 % 
confluence before the medium was replaced with ultraMEM for a further 24 h incubation. Cells were then 
prepared in situ and immunolabelled as indicated.  
  
- 138 - 
 
 As such, it was apparent that inhibiting APP release from the cell surface with 
batimastat did indeed result in a change in the subcellular distribution of 
immunofluorescence observed using the anti-APP WO2 antibody. This would suggest a 
degree of APP specificity to the antibody. 
 Having, optimised the immunofluorescence conditions, the effect of DCA on the 
subcellular localisation of APP was investigated. Here, cells were pre-incubated for 24 h with 
10 mM DCA. Note that both the batimastat and these DCA treatments were performed in the 
same experiment and, as such, the control images for the latter treatments are those already 
described in Fig. 6.3. The images from DCA-treated cells (Fig. 6.5.) showed no major changes 
in APP subcellular localisation compared to the control cells (Fig. 6.3.), with a possible 
decrease in cis-Golgi localisation. Therefore, it is unlikely that the drug regulates APP 
proteolysis by mediating the subcellular localisation of APP. 
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Figure 6.4. The localisation of APP in batimastat-treated SH-SY5Y cells. Human SH-SY5Y cells were initially 
grown to 60 % confluence before the medium was replaced with ultraMEM containing 5 M batimastat for a 
further 24 h incubation. Cells were then prepared in situ and immunolabelled as indicated.  





Figure 6.5. The localisation of APP in DCA-treated SH-SY5Y cells. Human SH-SY5Y cells were initially grown to 
60 % confluence before the medium was replaced with ultraMEM containing 10 mM for a further 24 h 
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6.3.  Summary. 
 The results in the current chapter clearly show that DCA did not alter overall cellular 
BACE1 activity although caution should be applied in interpreting this result as this does not 
preclude the possibility that the drug alters activity of the protein in different intracellular 
compartments. 
 A reliable method for the subcellular visualisation of APP distribution has been 
established and ADAM inhibition using batimastat clearly impacted on this distribution 
suggesting that APP was, indeed, being specifically visualised. However, the results also show 
that DCA exhibited no major effect on APP subcellular distribution. As such, it is unlikely that 
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7.  Mitochondrial autophagy and oxidative stress as possible mechanisms 
through which DCA regulates APP proteolysis. 
 It has recently been demonstrated that DCA induces mitochondrial autophagy in SH-
SY5Y cells (Pajuelo-Reguera et al., 2015). Prior studies have also identified a link between 
mitophagy and APP processing (Cole et al., 1989; Siman et al., 1993) and have implicated 
mitophagy in the progression of AD (Manczak et al., 2006; Chen et al., 2007; Petersen et al., 
2008). 
DCA has also been shown to enhance oxidative stress (Hassoun and Cearfoss, 2011; 
Dai et al., 2014) and it is well established that oxidative stress plays a role both in the 
development of AD and in APP proteolysis (Smith et al., 2007; Chen et al., 2008; Tamagno et 
al., 2008; Guglielmotto et al., 2009; Mouton Liger et al., 2012; Arimon et al., 2015; Muche et 
al., 2017; Cheignon et al., 2018). 
Therefore, in the current study, it was hypothesised that DCA might be regulating its 
effects on APP proteolysis through changes in mitochondrial autophagy and/or the 
enhancement of oxidative stress. To this end, SH-SY5Y cells were treated with DCA in the 
presence of mitophagy inhibitors or detoxifying free radical scavengers and the resultant 
effects on APP processing were characterised. 
 
7.1.  Mitochondrial autophagy and DCA-regulated APP processing. 
 To explore mitophagy as a potential mechanism by which DCA regulates APP 
proteolysis, SH-SY5Y cells were treated with two inhibitors of mitochondrial autophagy 
(ammonium chloride and chloroquine) and the effects of these compounds on the ability of 
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DCA to regulate APP proteolysis were monitored. The theory here was that, if the inhibitors 
prevented the mitophagy changes associated with DCA treatment, then they would also 
ablate the effects of the latter compound on APP proteolysis. 
 
7.1.1. Ammonium chloride. 
Here, SH-SY5Y cells were initially grown to confluence and treated for 24 h with 
UltraMEM containing DCA (10 mM) and/or ammonium chloride (10 mM). The concentration 
of the latter compound was adopted as it had previously been shown to block terminal 
autophagy phases in SH-SY5Y cells (Pajuelo-Reguera et al., 2015). Cell viability was then 
determined using the MTS assay as described in the Materials and Methods section. The 
results (Fig. 7.1.) showed that, as previously observed, DCA (10 mM) alone caused no 
decrease in cell viability. Furthermore, ammonium chloride did not alter viability either when 
used singularly or in combination with DCA. 
 
Figure 7.1. The effect of DCA and/or ammonium chloride treatment on SH-SY5Y cell viability. Cells were grown 
to confluence and then treated with DCA and/or ammonium chloride at the concentrations indicated in 
UltraMEM for 24 h. Cells were then quantified using an MTS assay in situ. Results are means ± S.D. (n=3). 
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 The same experiment was repeated but, this time, cells and conditioned medium were 
harvested. Cell lysates were prepared and immunoblotted to examine p53 levels. The results 
(Fig. 7.2.) show that, as previously observed, DCA alone enhanced p53 levels (113.17 ± 7.76 
% increase relative to controls). In contrast, ammonium chloride alone had no effect on p53 
levels nor did it alter the ability of DCA to promote levels of the protein.  
 
 
Figure 7.2. The effect of DCA and/or ammonium chloride treatment on the levels of p53 in SH-SY5Y cells. Cells 
were grown to confluence and then treated with DCA and/or ammonium chloride at the concentrations 
indicated in UltraMEM for 24 h. Cell lysates were then prepared and immunoblotted using the (A) anti-p53 and 
(B) anti-actin antibody as described in the Materials and Methods section. Results are means ± S.D. (n=3). 
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 The same lysates were also immunoblotted with the anti-APP C-terminal antibody to 
monitor any changes in the expression of full-length APP. The results (Fig. 7.3.) showed small 
increases in APP expression when cells were treated with DCA either alone or in combination 
with ammonium chloride (20.51 ± 3.55 and 26.08 ± 1.26 % increases, respectively, relative to 
controls). Cells treated with ammonium chloride did not exhibit altered APP expression nor 
did the compound modify the effect of DCA in this respect. 
 
 
Figure 7.3. The effect of DCA and/or ammonium chloride treatment on the expression of APP in SH-SY5Y cells. 
Cells were grown to confluence and then treated with DCA and/or ammonium chloride at the concentrations 
indicated in UltraMEM for 24 h. Cell lysates were then prepared and immunoblotted using the anti-APP C-
terminal antibody as described in the Materials and Methods section. Results are means ± S.D. (n=3). Significant 
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 Next, the effect of ammonium chloride and DCA on the proteolysis of APP was 
examined. To this end, concentrated conditioned medium from the preceding experiments 
was initially immunoblotted with anti-sAPPα 6E10 antibody. The results (Fig. 7.4.) showed 
that, as previously observed, DCA enhanced sAPPα production by cells (142.95 ± 56.14 and 
392.81 ± 18.33 % increases for sAPP695α and sAPP751/770α, respectively, relative to 
controls). Similarly, ammonium chloride treatment led to a 67.98 ± 16.23 % increase in the 
production of sAPP695α; however, the production of sAPP751/770α by these cells was not 
altered. Finally, whilst co-treatment of cells with DCA and ammonium chloride also resulted 
in enhanced sAPP695α and sAPP751/770α generation relative to controls (131.21 ± 41.99 % 
and 398.12 ± 69.15 %, respectively, for the two isoform groupings), these increments were 
not statistically different from the levels of these fragments generated when the cells were  
 
Figure 7.4. The effect of DCA and/or ammonium chloride treatment on the production of sAPPα by SH-SY5Y 
cells. Cells were treated with DCA and/or ammonium chloride at the concentrations indicated for 24 h. Equal 
volumes of concentrated medium were then immunoblotted with the anti-sAPPα 6E10 antibody. Results are 
means ± S.D.  (n=3). Significant results are indicated: * = significant at p ≤ 0.05, ** = significant at p ≤ 0.01, **** 
= significant at p ≤ 0.001.  
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treated with DCA alone. As such, it was apparent that, whilst ammonium chloride had a 
minimal but significant effect on sAPPα production, it did not modify the ability of DCA to 
promote shedding of these fragments. 
 Finally, the conditioned medium from these experiments was immunoblotted to 
quantify the relative levels of sAPPβ generated by cells. As observed previously, DCA inhibited 
the production of this fragment (Fig. 7.5.) (78.70 ± 2.24 % decrease relative to controls). 
However, ammonium chloride had no effect in this respect nor did it alter the ability of DCA 
to inhibit sAPPβ production.  
 
Figure 7.5. The effect of DCA and/or ammonium chloride treatment on the production of sAPPβ by SH-SY5Y 
cells. Cells were treated with DCA and/or ammonium chloride at the concentrations indicated for 24 h. Equal 
volumes of concentrated medium were then immunoblotted with the anti-sAPPβ antibody. Results are means 
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7.1.2. Chloroquine. 
 To further investigate the potential role of mitochondrial autophagy as a mechanism 
underlying the effects of DCA on APP proteolysis, the mitophagy inhibitor, chloroquine, was 
also studied. Cells were initially grown to confluence and treated for 24 h with UltraMEM 
containing DCA and/or chloroquine diphosphate (50 μM). Again, the concentration of the 
latter compound was adopted due to its previously demonstrated ability to block mitophagy 
in SH-SY5Y cells at this concentration (Pajuelo-Reguera et al., 2015). After 24 h, the viability 
of cultures was assessed using the MTS assay as described in the Materials and Methods 
section. The results (Fig. 7.6.) demonstrated that neither DCA nor the chloroquine 
diphosphate, used singularly or in combination, had any significant effect on cell viability. 
 
Figure 7.6. The effect of DCA and/or chloroquine diphosphate treatment on SH-SY5Y cell viability. Cells were 
treated with DCA and/or chloroquine diphosphate at the concentrations indicated for 24 h. Cells were then 
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 The preceding experiments were repeated but, this time, cells and conditioned 
medium were harvested and processed for immunoblotting. Initially, equal amounts of lysate 
protein were immunoblotted with the anti-p53 antibody. The results (Fig. 7.7.) show that, as 
previously observed, DCA enhanced p53 levels (108.15 ± 9.70 % increase relative to controls) 
but chloroquine diphosphate did not alter the levels of this protein. The latter compound also 
failed to modify the ability of DCA to enhance p53 levels (116.13 ± 27.81 % increase, relative 
to controls). 
 The same cell lysates were also immunoblotted with the anti-APP C-terminal antibody 
to quantify relative levels of APP holoprotein expression. The results (Fig. 7.8.), in this 
instance, showed no significant change in APP expression. 
 
Figure 7.7. The effect of DCA and/or chloroquine diphosphate treatment on the levels of p53 in SH-SY5Y cells. 
Cells were grown to confluence and then treated with DCA and/or chloroquine diphosphate at the 
concentrations indicated in UltraMEM for 24 h. Cell lysates were then prepared and immunoblotted using the 
(A) anti-p53 and (B) anti-actin antibodies as described in the Materials and Methods section. Results are means 
± S.D. (n=3). Significant results are indicated: * = significant at p ≤ 0.05, *** = significant at p ≤ 0.005. 
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Figure 7.8. The effect of DCA and/or chloroquine diphosphate treatment on the expression of APP in SH-SY5Y 
cells. Cells were grown to confluence and then treated with DCA and/or chloroquine diphosphate at the 
concentrations indicated in UltraMEM for 24 h. Cell lysates were then prepared and immunoblotted using the 
anti-APP C-terminal antibody as described in the Materials and Methods section. Results are means ± S.D. (n=3). 
 
 The concentrated conditioned medium from the preceding experiments was then 
immunoblotted to quantify the generation of sAPPα and sAPPβ. The samples were first 
immunoblotted with the anti-sAPPα 6E10 antibody and the results (Fig. 7.9.) showed that, as 
previously observed, DCA enhanced the generation of sAPPα (99.18 ± 34.94 and 129.67 ± 
37.64 % increases, respectively, for sAPP695α and sAPP751/770α, relative to controls). When 
used alone, chloroquine diphosphate slightly enhanced sAPP751/770α generation (75.18 ± 
28.31 % increase relative to controls) but had no significant effect on the generation of 
sAPP695α. Notably, the co-treatment of cells with both DCA and chloroquine diphosphate did 
not alter the ability of DCA to promote sAPPα generation. 
  




Figure 7.9. The effect of DCA and/or chloroquine diphosphate treatment on the production of sAPPα by SH-
SY5Y cells. Cells were treated with DCA and/or chloroquine diphosphate at the concentrations indicated for 24 
h. Equal volumes of concentrated medium were then immunoblotted with the anti-sAPPα 6E10 antibody. 
Results are means ± S.D.  (n=3). Significant results are indicated: * = significant at p ≤ 0.05.  
 
 When the conditioned medium was immunoblotted with the sAPPβ antibody the 
results (Fig. 7.10.) again demonstrated the ability of DCA to inhibit production of this 
fragment. However, used singularly, chloroquine diphosphate did not alter the generation of 
this fragment nor did it modify the effect of DCA in this respect. 
Collectively, these results indicate that DCA does not alter APP proteolysis via 
mechanisms linked to cellular mitophagy with the caveat that the latter event was not 
quantified in the current experiments. 
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Figure 7.10. The effect of DCA and/or chloroquine diphosphate treatment on the production of sAPPβ by SH-
SY5Y cells. Cells were treated with DCA and/or chloroquine diphosphate at the concentrations indicated for 24 
h. Equal volumes of concentrated medium were then immunoblotted with the anti-sAPPβ antibody. Results are 
means ± S.D. (n=3). Significant results are indicated: *** = significant at p ≤ 0.005. 
 
 
7.2.  Oxidative stress and DCA-regulated APP processing. 
 A previous study by Hassoun and Cearfoss (2011) demonstrated that DCA enhances 
oxidative stress and ROS production. Given that oxidative stress has also been shown to alter 
APP proteolysis (Chen et al., 2008; Tamagno et al., 2008; Guglielmotto et al., 2009; Mouton 
Liger et al., 2012; Kanamaru et al., 2015; Muche et al., 2017) it was, therefore, hypothesised 
in the current study that DCA might regulate APP proteolysis through the enhancement of 
oxidative stress. To this end, the abilities of two free radical scavengers, dimethyl sulfoxide 
(DMSO) and N-acetylcysteine (NAC), to modify the effects of DCA on APP proteolysis were 
examined. 
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7.2.1.  DMSO. 
 Initially, SH-SY5Y cells were grown to confluence and treated with UltraMEM 
containing DCA and/or DMSO (3 mM) for 24 h. This DMSO concentration was adopted as 
previous studies have demonstrated a free radical scavenging protective effect at similar 
concentrations (Jorns et al., 1999). Initially, cell viability was determined using the MTS assay 
as described in the Materials and Methods section. The results (Fig. 7.11.) showed that 
neither DCA nor DMSO affected viability when the reagents were used singularly. However, 
when the cells were co-treated with both reagents, there was a 37.36 ± 8.13 % decrease in 
viability (relative to controls), which was significantly different from controls, DCA alone and 
DMSO alone.  
 The same experiments were then repeated on a larger scale and this time cells and 
conditioned medium were harvested. Cell lysates were prepared and equal amounts of 
protein from these samples were immunoblotted with the anti-p53 antibody. The results (Fig. 
7.12.) show that, as previously observed, DCA enhanced p53 levels (76.72 ± 15.52 %, 
 
Figure 7.11. The effect of DCA and/or DMSO treatment on SH-SY5Y cell viability. Cells were treated with DCA 
and/or DMSO at the concentrations indicated for 24 h. Cells were then quantified using an MTS assay in situ. 
Results are means ± S.D. (n=3). Significant results are indicated: ****** = significant at p ≤ 0.0001. 
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relative to controls). However, DMSO alone did not impact on p53 levels nor did it modify the 
ability of DCA to enhance levels of the protein when the two compounds were used in 
combination (70.85 ± 17.40 % increase, relative to controls). 
 The cell lysate samples were then immunoblotted with the anti-APP C-terminal 
antibody to identify any changes in APP holoprotein expression. However, the results showed 
no significant changes in APP expression in these experiments (Fig. 7.13.).  
 The effects of DCA and DMSO on APP proteolysis were then assessed by 
immunoblotting equal volumes of concentrated conditioned medium samples with the anti-
APP 6E10 and anti-sAPPβ antibodies. 
 
 
Figure 7.12. The effect of DCA and/or DMSO treatment on the expression of p53 in SH-SY5Y cells. Cells were 
grown to confluence and then treated with DCA and/or DMSO at the concentrations indicated in UltraMEM for 
24 h. Cell lysates were then prepared and immunoblotted using the (A) anti-p53 and (B) anti-actin antibodies as 
described in the Materials and Methods section. Results are means ± S.D. (n=3). Significant results are indicated: 
* = significant at p ≤ 0.05. 
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Figure 7.13. The effect of DCA and/or DMSO treatment on the expression of APP in SH-SY5Y cells. Cells were 
grown to confluence and then treated with DCA and/or DMSO at the concentrations indicated in UltraMEM for 
24 h. Cell lysates were then prepared and immunoblotted using the anti-APP C-terminal antibody as described 
in the Materials and Methods section. Results are means ± S.D. (n=3). 
 
 Initial results using the former antibody (Fig. 7.14A.) showed that DCA enhanced 
sAPPα production (156.73 ± 39.46 and 112.20 ± 28.01 % increases, respectively, for sAPP695α 
and sAPP751/770α relative to controls). DMSO did not modify the ability of DCA in this 
respect and used singularly had no effect on the production of these fragments, before and 
after viability correction (Fig. 7.14B.). 
 The conditioned medium was then immunoblotted with the anti-sAPPβ antibody.  The 
results (Fig. 7.15A.) showed that there were significant decreases in sAPPβ production in cells 
treated with both DCA and DCA with DMSO (66.38 ± 11.72 and 77.50 ± 11.50 % reductions, 
respectively, relative to controls). These differences remained after correcting for cell viability 
(Fig. 7.15B.) (66.38 ± 11.72 and 63.77 ± 18.51 %). However, DMSO alone did not alter sAPPβ 
production nor did it modify the ability of DCA to reduce the production of this fragment. 
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Figure 7.14. The effect of DCA and/or DMSO treatment on the production of sAPPα by SH-SY5Y cells. Cells 
were treated with DCA and/or DMSO at the concentrations indicated for 24 h. Equal volumes of concentrated 
medium were then immunoblotted with the anti-sAPPα 6E10 antibody. (A) Standard results. (B) Viability 
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Figure 7.15. The effect of DCA and/or DMSO treatment on the production of sAPPβ by SH-SY5Y cells. Cells 
were treated with DCA and/or DMSO at the concentrations indicated for 24 h. Equal volumes of concentrated 
medium were then immunoblotted with the anti-sAPPβ antibody. (A) Standard results. (B) Viability corrected 
results. Results are means ± S.D.  (n=3). Significant results are indicated: * = significant at p ≤ 0.05, *** = 
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7.2.2. NAC. 
 To further investigate the potential role of oxidative stress and ROS production as a 
mechanism by which DCA alters APP proteolysis, a second free radical scavenger, N-acetyl 
cysteine (NAC), was employed. These experiments were conducted in an identical manner to 
those in the preceding section except that the DMSO was replaced with 1 mM NAC 
(concentration adopted from Stephenson et al., 2013).  
 Cell viability results (Fig. 7.16.) showed that, used singularly, neither DCA nor NAC 
influenced cell viability. However, as was the case with DMSO, the free radical scavenger NAC, 
appeared to work synergistically with DCA to reduce cell viability (54.01 ± 6.19 % decrease, 
relative to controls).  
 
Figure 7.16. The effect of DCA and/or NAC treatment on SH-SY5Y cell viability. Cells were treated with DCA 
and/or NAC at the concentrations indicated for 24 h. Cells were then quantified using an MTS assay in situ. 
Results are means ± S.D. (n=3). Significant results are indicated: *** = significant at p ≤ 0.005, ******* = 
significant a p ≤ 0.00005, ********** = significant at p ≤ 0.000005. 
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Next, the effects of NAC and DCA treatment on the levels of p53 in cell lysates were 
investigated. The results (Fig. 7.17.) showed that DCA alone enhanced p53 levels by 205.97 ± 
74.80 %, relative to controls. Interestingly, NAC, used singularly, also enhanced p53 levels 
(155.94 ± 53.95 %, relative to controls). However, the effects of the two compounds were not 
additive in that co-treatment of cells enhanced p53 levels to the same extent as either 
compound used singularly (144.52 ± 35.34 % relative to controls). 
The same cell lysates were also immunoblotted with the anti-APP C-terminal antibody. 
However, the results (Fig. 7.18.) showed no significant changes in APP expression. 
 
Figure 7.17. The effect of DCA and/or NAC treatment on the levels of p53 in SH-SY5Y cells. Cells were grown 
to confluence and then treated with DCA and/or NAC at the concentrations indicated in UltraMEM for 24 h. Cell 
lysates were then prepared and immunoblotted using the (A) anti-p53 and (B) anti-actin antibody as described 
in the Materials and Methods section. Results are means ± S.D. (n=3). Significant results are indicated: * = 
significant at p ≤ 0.05. 
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Figure 7.18. The effect of DCA and/or NAC treatment on the expression of APP in SH-SY5Y cells. Cells were 
grown to confluence and then treated with DCA and/or NAC at the concentrations indicated in UltraMEM for 24 
h. Cell lysates were then prepared and immunoblotted using the anti-APP C-terminal antibody as described in 
the Materials and Methods section. Results are means ± S.D. (n=3). 
 
 
 Next, the levels of sAPPα in concentrated conditioned medium samples were 
analysed. The results (Fig. 7.19A.) showed that, as usual, DCA enhanced the production of 
both sAPP695α and sAPP751/770α (44.39 ± 17.84 and 33.38 ± 9.02 % increases, respectively, 
relative to controls); the significance of these results also remained after adjusting for changes 
in cell viability (Fig. 7.19B.). There changes were not affected by NAC treatment and, when 
used on its own, NAC had no effect on the production of sAPPα.  
 The same conditioned medium samples were then immunoblotted with the anti-
sAPPβ antibody. The results (Fig. 7.20.) show that, as previously observed, DCA prevented the 
accumulation of this fragment but NAC had no significant effect in this respect, nor did it alter 
the ability of DCA to reduce levels of the fragment. 
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Figure 7.19. The effect of DCA and/or NAC treatment on the production of sAPPα by SH-SY5Y cells. Cells were 
treated with DCA and/or NAC at the concentrations indicated for 24 h. Equal volumes of concentrated medium 
were then immunoblotted with the anti-sAPPα 6E10 antibody. (A) Standard results. (B) Viability corrected 
results. Results are means ± S.D.  (n=3). Significant results are indicated: * = significant at p ≤ 0.05. 
 




Figure 7.20. The effect of DCA and/or NAC treatment on the production of sAPPβ by SH-SY5Y cells. Cells were 
treated with DCA and/or NAC at the concentrations indicated for 24 h. Equal volumes of concentrated medium 
were then immunoblotted with the anti-sAPPβ antibody. (A) Standard results. (B) Viability corrected results. 
Results are means ± S.D.  (n=3). Significant results are indicated: * = significant at p ≤ 0.05, ** = significant at p ≤ 
0.01, **** = significant at p ≤ 0.001. 
 
7.3.  Summary.  
 The first part of this chapter investigated the ability of inhibitors of terminal mitophagy 
(ammonium chloride and chloroquine diphosphate) to modify the effects of DCA on APP 
proteolysis. Neither of these compounds had any effect on cell viability whether used 
singularly or in combination with DCA. Similarly, whereas DCA routinely enhanced p53 levels, 
the two mitophagy inhibitors had no effect in this respect, nor did they modify the ability of 
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DCA to alter p53 levels. Similarly, neither ammonium chloride nor chloroquine diphosphate 
had any effect on APP holoprotein expression. When used singularly, both compounds 
resulted in small but significant increases in sAPPα production. However, neither compound 
significantly modified the effects of DCA in this respect. Similarly, neither compound altered 
the ability of DCA to reduce sAPPβ production. With the caveat that mitochondrial autophagy 
was not actually monitored in the current study, it would seem that these inhibitors of the 
process did not affect the ability of DCA to modify APP proteolysis. As such, these data would 
seem to support the fact that mitochondrial autophagy is not mechanistically involved in the 
effects of DCA in this context. 
 In terms of oxidative stress, it is notable that, whilst neither free radical scavenger 
(DMSO or NAC) had any impact on cell viability when used singularly, both seemed to work 
synergistically with DCA to reduce viability. Interestingly though, DMSO did not modify p53 
levels whether used singularly or in conjunction with DCA (the latter being compared to 
treatments using DCA alone). In contrast, NAC enhanced p53 levels when used singularly but 
did not further enhance the ability of DCA to enhance the levels of this protein. Neither of the 
two free radical scavengers modified APP expression, sAPPαor sAPPβ production, or the 
ability of DCA to alter production of either fragment. In conclusion, despite minor changes in 
APP proteolysis, it is unlikely that the effects of DCA in this respect are mechanistically linked 
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 8. Discussion. 
 The orphan drug dichloroacetate has recently been shown to minimise the 
detrimental amyloidogenic APP processing pathway, whilst enhancing the neuroprotective 
non-amyloidogenic APP processing pathway (Parkin et al., unpublished). However, the 
mechanism underlying these changes has not been determined. The current project, 
therefore, aimed to establish how, at the molecular level, DCA exerts its effects on APP 
proteolysis. 
 
8.1.  Characterisation of DCA action in SH-SY5Y cells. 
 Initially, the effects of DCA on cell viability, p53 and APP expression/proteolysis were 
fully characterised in SH-SY5Y cells. The drug did not reduce cell viability at either of the two 
(10 or 20 mM) concentrations used (Fig. 3.1.), contrasting with previous reports (Pajuelo-
Regura et al., 2015) which demonstrated significant decreases in SH-SY5Y cell viability even 
at 5 mM DCA. Whilst there is no obvious explanation for these differences, factors such as the 
degree of cell confluency may dictate the sensitivity of SH-SY5Y cells to DCA toxicity (entirely 
confluent cells were used in the current study). It is notable, however, that slight decreases 
in viability were observed when using the alternate Trypan blue method for determining cell 
viability (Fig. 3.1.), suggesting that some cells may have undergone apoptosis, detached from 
the flask base and been replaced by other cells in the confluent layer. This may also be 
indicated by the fact that DCA appeared to enhance p53 expression in the current study, an 
observation that corroborates previous reports (Agnoletto et al., 2014).  
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 The most interesting results here are that DCA enhanced non-amyloidogenic and 
inhibited amyloidogenic APP processing (Figs. 3.4, 3.5, 3.8, and 3.9.). Given that apoptosis has 
previously been associated with the amyloidogenic processing of APP and Aβ generation 
(reviewed by Obulesu and Lakshmi, 2014), these observations are somewhat counterintuitive 
in this respect.   
 
8.2.  pH as a possible mediator of DCA action. 
 Sodium dichloroacetate is a conjugate base of dichloroacetic acid and, as was 
observed in the current study, might be expected to increase the pH of conditioned cell 
culture medium (Fig. 3.10.). Alternatively, previous work has attributed the DCA-mediated 
increases in extracellular and intracellular pH to reductions in lactate levels due to PDH 
stimulation (Robey and Martin, 2011; Albatany et al., 2018). Regardless of the cause of the 
pH alteration, however, the current study hypothesised that such a change might be 
responsible for the observed effects of DCA on APP proteolysis. To this end, the effects of two 
related compounds (sodium acetate and acetic acid) on pH and APP proteolysis were 
examined. 
 As would be expected for another conjugate base, sodium acetate resulted in similar 
increases in the pH of conditioned medium to those affected by DCA (Fig. 3.12.) and only 
minor decreases in cell viability (Fig. 3.13.). It is interesting to note that sodium acetate 
actually decreased cellular p53 levels (Fig. 3.15.), compared to the enhanced levels caused by 
DCA. This would indicate that DCA affected the levels of the protein via a mechanism 
unrelated to pH change; possibly linked to PDH inhibition, promotion of mitochondrial 
respiration/function and ROS production (Wong et al., 2008). However, the fact remains that 
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sodium acetate actually impaired p53 expression, possibly by increasing the alkalinity of the 
extracellular solution, although there is scant information in the literature to support or refute 
this hypothesis.  
 In contrast to both DCA and sodium acetate, the treatment of cells with acetic acid led 
to the expected acidification of medium (Fig. 3.19.) with an associated decrease in cell viability 
(Fig. 3.20.). Notably, however, the levels of p53 were decreased rather than increased (Fig. 
3.22.), suggesting that the observed decreases in cell viability were due to necrotic rather 
than apoptotic cell death, as the former form is not commonly associated with p53 (reviewed 
by Ying and Padanilam, 2016). 
 Turning to the effects of the three compounds on APP expression, it was notable that 
both DCA and acetic acid enhanced expression despite having opposing effects on pH (Figs. 
3.2. and 3.21.), whilst sodium acetate did not alter APP expression (Fig. 3.14.) despite 
affecting pH in the same manner as DCA. Previous observations (Schrader-Fischer et al., 1996) 
suggested that alkalising agents may result in an accumulation of APP, which corroborates 
the DCA results but contrasts with the sodium acetate results in the current study. As these 
compounds had a similar effect on pH but opposing effects on APP expression, this clearly 
demonstrates that any observed effects of DCA upon APP expression in this study are not 
simply correlated to changes in pH. 
 As far as non-amyloidogenic APP processing is concerned, both alkalinising agents 
used in the current study enhanced sAPPα production by cells (Figs. 3.4. and 3.16.), albeit the 
changes with sodium acetate were not in the same order of magnitude as with DCA. This 
suggests that the effect of DCA in this respect may be mediated by enhanced pH, agreeing 
with previous observations (Schrader-Fischer et al., 1996) which suggested alkalising 
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treatments increased non-amyloidogenic APP processing. However, it should be noted that 
acetic acid also enhanced sAPPα production in the current study (Fig. 3.23.), suggesting a 
more complex relationship between pH and non-amyloidogenic APP processing.  
 Regarding amyloidogenic APP processing, the alkalising agents had opposing effects, 
with sodium acetate increasing and DCA reducing sAPPβ production (Figs. 3.5. and 3.17.). 
Previous investigations (Schrader-Fischer et al., 1996) reported reduced amyloidogenic 
processing following alkalising treatments, corroborating the DCA results but again 
contrasting with sodium acetate results in the current study. These differences may be 
explained by differential treatment times (4 h in the case of Schrader-Fischer et al. and 24 h 
in the current study), or the effects of different pH-modulating compounds (Schrader-Fischer 
et al. used ammonium chloride).  
 An increase in sAPPβ production was also observed following acetic acid treatment in 
the current study (Fig. 3.24.). This is consistent with previous studies which reported 
enhanced amyloidogenic processing following acidifying treatments, attributed to optimal 
BACE-1 activity at pH 6 (Brown et al., 1998; Lin et al., 2000; Xiang et al., 2010). 
 Overall, as sodium acetate and acetic acid had similar effects on APP proteolysis 
(despite having opposing effects on pH), and DCA and sodium acetate had different effects 
on APP proteolysis (despite having similar effects on pH), it is clear that the effects of DCA on 
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8.3.  The interaction between p53 and APP expression/proteolysis. 
 As DCA enhanced p53 levels in the current study, the ability of RITA to upregulate 
levels of this protein and alter APP proteolysis in SH-SY5Y cells was examined. As would be 
expected in cells with enhanced levels of apoptotic-regulating p53, decreases in viability were 
observed at RITA concentrations ≥10 µM (Fig. 4.1.). In contrast, a previous report (Burmakin 
et al., 2013) observed significant decreases in SH-SY5Y viability at just 1 µM RITA. These 
conflicting results, however, may be due to several differing factors, such as total treatment 
time (48 h used by Burmakin et al. and 24 h used in the current study) and degree of 
confluency (cells treated at the point of seeding by Burmakin et al. compared to 100 % 
confluency in the current study).  
 Interestingly, RITA and DCA appeared to act synergistically to dramatically decrease 
viability (Fig. 4.7.). This might be explained by the additive increase in p53 levels following co-
treatment with the two compounds (Fig. 4.8.). 
 RITA did not alter APP expression (Fig. 4.3.) or modify the DCA-associated changes in 
this respect (Fig. 4.9.). This seems to contrast with previous work by Cuesta et al. (2009), who 
observed increased APP expression following p53 accumulation. However, the authors 
treated SH-SY5Y cells with camptothecin, leading to a much stronger accumulation and 
activation of p53 (10-fold increase in p53 compared to the 2/3-fold increase with RITA and/or 
DCA treatments in the current study). In the context of the current study, as RITA treatments 
did not enhance APP expression despite enhancing p53 levels to a similar degree as DCA, it is 
unlikely that the latter compound regulates APP expression through the enhancement of p53 
levels. 
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 When the effects of RITA on the proteolysis of APP were investigated, no significant 
differences in sAPPα or sAPPβ production were observed (Figs. 4.4. and 4.5.). Interestingly, 
Checler et al. (2010) suggested that increased p53 expression regulated γ-secretase activity, 
with enhanced PS1 and PEN-2 expression and transactivation of several members of the 
complex. Although these observations could explain the parallel increases in p53 and Aβ 
aggregation observed within the brains of AD patients (Ohyagi et al., 2005), the current study 
suggests that enhancing p53 levels does not mediate APP proteolysis or modify the DCA-
associated changes (Figs. 4.10. and 4.11.).  
 It was noted that the sAPPβ blots from the RITA experiments in the current study 
contained an increase in an unknown band located at 30 kDa (Fig. 4.6A.). It was hypothesised 
that this fragment might be generated from a cleavage of sAPPβ, resulting in the production 
of two fragments; a C-terminal 30 kDa fragment (containing the sAPPβ antibody epitope) and 
an N-terminal 70 kDa fragment. Although previous literature has suggested alternative 
pathways of APP proteolysis (Andrew et al., 2016), a 30 kDa sAPPβ fragment has not been 
reported. Upon immunoblotting with the 22C11 antibody, no corresponding 70 kDa N-
terminal fragment was observed (Fig. 4.6B.) but numerous smaller fragments around 15-20 
kDa were detected following RITA treatment. This raised the possibility that the N-terminal 
fragment produced may have been rapidly degraded and, therefore, not detected as an intact 
70 kDa band. 
 In the current study, siRNA experiments were also employed to examine the effects 
of p53 depletion on APP expression/proteolysis. Interestingly, siRNA treatment almost 
completely ablated cellular p53 levels in the absence of DCA treatment. However, when cells 
were subjected to p53 siRNA treatment followed by treatment with DCA, control levels of the 
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p53 protein were restored (Fig. 4.16.). A prior investigation (Agnoletto et al., 2014) 
demonstrated increased p53 levels following DCA treatment, suggesting it was a result of 
enhanced TP53 gene transcription. In the current study, however, de novo production of p53 
was inhibited and yet levels still increased, suggesting that DCA enhances levels of the protein 
via a post-translational mechanism. Several other drugs have been shown to enhance p53 
levels by hindering the degradation of the protein; for example, Nutlins hinder degradation 
by preventing interaction between p53 and MDM2, whist MDM2 E3 ubiquitin ligase inhibitors 
prevent ubiquitinylation of p53 and hence prevent degradation via the proteasome (Wang 
and Sun, 2010). Therefore, it is possible that DCA may also control p53 at the level of turnover. 
 Depleting p53 expression in the current study did not affect APP expression, with or 
without DCA treatment (Fig. 4.17.). This contrasts with previous work (Cuesta et al., 2009), 
which demonstrated an increase in APP promotor activity following the expression of a 
dominant-negative p53 mutant. Furthermore, p53 siRNA did not mediate the DCA-associated 
changes in APP proteolysis products (Figs. 4.18. and 4.19.). However, as DCA treatments 
returned the levels of p53 to control levels following p53 siRNA treatments, the contribution 
of lower p53 levels on the metabolism of APP cannot be fully assessed.  
 Overall, the current study indicates that p53 is not responsible for the changes in APP 
proteolysis mediated by DCA.  
 
8.4. The association between lactic acid, pyruvate and APP processing. 
 In the current study, cells were treated with LDH inhibitors to alter the levels of lactate 
and pyruvate and determine the subsequent effects on APP expression/proteolysis. Whilst 
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the GSK2837808A inhibitor had no effect on SH-SY5Y cell viability and p53 levels (Figs. 5.1. 
and 5.2.), FX11 treatment dramatically reduced viability at higher concentrations (≥ 10 µM) 
and increased p53 levels (Figs. 5.6. and 5.7.). These findings suggest that LDH-A inhibition 
stimulates apoptosis, agreeing with previous observations that LDH-A inhibition blocks 
aerobic glycolysis (Brighenti et al., 2017) and stimulates oxidative stress and cellular death (Le 
et al., 2010). As these toxic effects were not observed in cells treated with the GSK2837808A 
inhibitor, this suggests that the inhibition of LDH-B possibly outweighed the effects of LDH-A 
inhibition and protected cells from viability changes. 
GSK2837808A-treated cells exhibited decreased sAPPα production, whilst FX11-
treated cells exhibited increased sAPPα production at sub-toxic (1 μM) levels of the inhibitor 
and decreased production at toxic (10 μM) levels (Figs. 5.4. and 5.9.). Comparatively, sAPPβ 
production was enhanced at all concentrations ≥ 10 nM in GSK2837808A-treated cells, but 
not altered in FX11 cells (Figs. 5.5. and 5.10.). Therefore, as with DCA, the results are 
somewhat counterintuitive in terms of apoptosis, with no viability differences observed at 
sAPPβ-enhancing GSK2837808A concentrations but apoptosis observed in FX11 treatments 
where sAPPβ was not altered. It is also interesting to note that amyloidogenic processing of 
APP only increased when both LDH-A and LDH-B were inhibited, suggesting that inhibition of 
LDH-B was responsible for these changes. Whereas previous studies have reported enhanced 
LDH-A activity in AD patients (Bigl et al., 1999) and Aβ resistance in patients with enhanced 
LDH activity (Soucek et al., 2003), our results demonstrate a complex interaction between 
LDH-A, LDH-B and the processing of APP. 
 Cells were next treated with pyruvate and the effects on APP expression/proteolysis 
were characterised. Viability was dramatically reduced in cells treated with pyruvate at higher 
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concentrations (Fig. 5.11.), correlating with increased p53 levels (Fig. 5.12.), suggesting 
enhanced apoptosis.  A previous study by Wszelaki and Melzig (2013) actually identified a 
protective effect of pyruvate against neurotoxicity in SH-SY5Y cells and saw no viability 
changes up to 1 mM pyruvate. However, toxic concentrations identified in the current study 
were much higher (50 and 100 mM), and 10 mM pyruvate actually enhanced viability, 
agreeing with the suggested protective role of the compound. 
 In terms of APP proteolysis products, pyruvate yielded the opposite effects to those 
of DCA, with reduced sAPPα production following viability correction and increased sAPPβ 
production before viability correction (Figs. 5.14. and 5.15.). It was therefore hypothesised 
that DCA may alter APP processing by enhancing PDH activity and consequentially lowering 
pyruvate levels. However, as no prior studies have investigated a link between the levels of 
pyruvate and APP expression/proteolysis, this hypothesis cannot be confirmed nor refuted. 
 The next stage of the current study involved the treatment of cells with lactic acid in 
the presence of DCA and the characterisation of the resultant effects on APP 
expression/proteolysis. Very slight but significant decreases in viability were observed in cells 
treated for 24 h with DCA and lactic acid (at both 6 and 12 mM concentrations), and 12 mM 
lactic acid alone (Fig. 5.16.). This contrasts with prior observations (Xiang et al., 2010) in which 
no viability differences were obtained following 6 h treatments with lactic acid at the same 
concentrations.  
 Interestingly, although lactic acid did not impact on the DCA-mediated increase in p53, 
cells treated with lactic acid alone also exhibited enhanced p53 levels (Fig. 5.17.). No prior 
studies have directly demonstrated an increase in p53 expression following lactic acid 
treatment and so these results cannot be confirmed nor refuted. 
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  In terms of APP, lactic acid did not alter the DCA-mediated effects upon APP 
expression and proteolysis (Figs. 5.18-5.20.). Furthermore, neither APP expression nor sAPPα 
production were altered by lactic acid treatment, contrasting with a previous report (Xiang et 
al., 2010) in which lactic acid increased levels of APP and Aβ, and decreased levels of sAPPα. 
However, as this paper had treated cells for 6 h with lactic acid (rather than 24 h), it was 
hypothesised that lactic acid may have been metabolised after 6 h, losing the effects on APP. 
Therefore, the studies in the current report were repeated over a 6 h time course. Again, very 
small but significant decreases in viability were observed in cells treated with lactic acid alone 
or in combination with DCA (Fig. 21.), accompanied by p53 level increases (Fig.  5.22.). This 
contrasts with the viability data from Xiang et al. (2010), who identified no viability changes 
at the same concentrations. However, the data presented in this latter paper did demonstrate 
a general trend for decreasing viability with large error bars which may have prevented the 
identification of significance.  
 The 6 h time course lactic acid experiments in the current study demonstrated a 
decreased cellular generation of sAPPα after lactic acid treatment akin to that observed by 
Xiang et al. (2010). However, it is notable that the latter authors did not identify and adjust 
their result for cell viability; when the results in the current study were adjusted in this 
respect, any effect of lactic acid on sAPPα generation lost significance. This may have resulted 
in an artefactual lactic acid-mediated effect on APP proteolysis.   
 Overall, these results suggest complex interactions between LDH activity, lactic acid, 
pyruvate and APP processing. As pyruvate treatment appeared to enhance amyloidogenic 
processing in the current study, DCA may mediate APP proteolysis via enhancing PDH activity 
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and thereby lowering pyruvate levels. Future studies should, therefore, investigate if pyruvate 
pre-treatment circumvents the DCA-mediated effects on APP proteolysis. 
 
8.5. DCA and APP localisation. 
 In the current study, cells were treated with DCA and the effects on APP localisation 
were investigated. Control cells (Fig. 6.3.) contained APP within the early endosomes and the 
cis-Golgi, agreeing with previous papers (Greenfield et al., 1999; Haass et al., 2012). However, 
very minimal APP was observed within the lysosomes, contrasting with previous work which 
demonstrated that APP localises within the lysosomes before it is degraded (Haass et al., 
1992; Lorenzen et al., 2010). However, Haass et al. prevented the breakdown of the APP 
within the lysosomes with leupeptin, and Lorenzen et al. used APP-transfected cells. 
Therefore, APP in the current study may have been rapidly degraded following internalisation 
in the lysosome or the amount may have been too small to be detected. 
 When cells were treated with batimastat (which prevents APP shedding) (Fig. 6.4.), a 
much stronger localisation of the APP within the endosome was observed. Furthermore, 
these cells were the only samples which identified APP within the lysosomes, potentially 
explained by less APP shedding via α-secretase leading to more reinternalisation.  
 Finally, when cells treated with DCA (Fig. 6.5.) were compared to control cells (Fig. 
6.3.), the results showed a marginal decrease in APP within the cis-Golgi. However, no other 
significant changes in APP location were identified, suggesting that DCA does not medicate 
APP processing by altering the subcellular localisation of the APP secretase substrate. 
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 It is worth noting that the effect of DCA on BACE1 localisation was not investigated in 
the current study due to the exceedingly low endogenous BACE1 levels in SH-SY5Y cells. 
Although this issue may have been overcome by using BACE1-overexpressing SH-SY5Y cells, 
previous work in our laboratories (Parkin et al., unpublished) demonstrated that BACE1 
overexpression negated the effects of DCA. 
 
8.6. DCA-induced mitophagy and APP expression/proteolysis. 
 In the current study, cells were treated with DCA in the presence of autophagy 
inhibitors (adopted from Pajuelo-Reguera et al., 2015) to investigate the role of this 
phenomenon in the DCA-regulated proteolysis of APP. Viability decreases were observed in 
cells treated with both 10 mM ammonium chloride and 50 µM chloroquine, both alone and 
in combination with DCA (Figs. 7.1. and 7.6.). However, no significant increases in p53 levels 
were observed in cells treated with either inhibitor (Figs. 7.2. and 7.7.), potentially suggesting 
that these viability differences were due to necrosis, as this form of cell death is not commonly 
associated with changes in p53 levels (reviewed by Ying and Padanilam, 2016).  
 Cellular treatments with ammonium chloride or chloroquine also revealed no effects 
upon APP expression/proteolysis (Figs. 7.3-7.5. and 7.8-7.10.), contrasting with previous 
studies where autophagy inhibition reduced Aβ production (Cole et al., 1989; Siman et al., 
1993). These differences, however, may be due to several factors; for example, these papers 
used cell lines overexpressing APP (PC12 and HCT293), which were treated with higher 
ammonium chloride concentrations (50 mM) for longer treatment periods (48 h). The current 
results, therefore, suggest that the mechanism by which DCA mediates APP proteolysis is not 
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related to mitochondrial autophagy, with the caveat that the ability of ammonium chloride 
and chloroquine to impair autophagy in the current study was not qualified. 
 
8.7.   ROS production as a potential mediator of DCA-regulated APP 
 proteolysis. 
 In the current study, the free radical scavengers DMSO and NAC both demonstrated 
synergistic cytotoxicity when used in combination with DCA (Figs. 7.11. and 7.16.). However, 
cells co-treated with DCA and DMSO or NAC exhibited similar increases in p53 levels to those 
treated with DCA alone (Figs. 7.12. and 7.17.), suggesting that the synergistic toxicity was a 
result of necrosis rather than apoptosis. 
 Neither DMSO nor NAC altered APP expression/proteolysis or modified the effects of 
DCA in these respects (Figs. 7.13-7.15. and 7.18-7.20.) which leads to the conclusion that DCA 
does not mediate such processes via oxidative stress and ROS production. 
 
8.8.  Concluding remarks and future perspectives. 
 In the current study, the possible mechanisms behind the DCA-mediated changes in 
APP proteolysis have been investigated. Although the mechanism has not been identified, we 
have demonstrated that these changes are not attributed to changes relating to culture 
medium pH, p53 activity, lactic acid/pyruvate metabolism, mitochondrial morphology, BACE1 
activity, APP localisation or production of ROS. However, several mechanistic possibilities still 
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require further investigation, such as the effect of DCA on BACE1 localisation and the effects 
of pyruvate and DCA co-treatment on the proteolysis of APP.  
 Additionally, this current study has led to several interesting results in relation to 
possible cancer treatments. For example, the cytotoxic synergism between RITA and DCA and 
their additive effects on p53 levels, the potential post-translational effects of DCA on p53, the 
induction of apoptosis and p53 expression via LDH-A inhibition, the enhancement of p53 
expression via lactic acid, and the synergistic effects of DMSO/NAC and DCA on cytotoxicity.  
 Overall, the findings in the current study (and previous unpublished data) have 
demonstrated that DCA enhances non-amyloidogenic processing and reduces amyloidogenic 
processing. Therefore, future investigations into the mechanism could still provide key 
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9. Appendices. 




Figure 8.1. DCA circumvents the decrease in p53 expression mediated by p53 siRNA. SH-SY5Y cells were grown 
to 70 % confluence and then transfected with p53 siRNA as described in the Materials and Methods section. 
After a penultimate 48 h incubation in complete growth medium, the cells were incubated for a further 24 h in 
UltraMEM in the absence or presence of 10 mM DCA. Equal amounts of cell lysate protein were then subjected 
to SDS-PAGE and immunoblotting using anti-p53 (see Materials and Methods). Results are means ± S.D. (n=3). 
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